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Vaccines are beginning to be explored for cancer prevention.  Since the time between 
vaccination and determination of efficacy is long, there is a need for predictive early biomarkers. 
Immunological endpoints that are determined weeks or months post vaccination are currently 
being evaluated as biomarkers of vaccine efficacy to replace disease outcome that could take 
years to assess.  However, when multiple vaccines are available, waiting for the development of 
humoral and cellular immunity could still cause delays while an earlier assessment would allow a 
timely change to a more effective prevention modality.  We hypothesize that early activation of 
signaling networks within T cells in response to immunization predicts the outcome of the 
immune response and may be used as a biomarker of vaccine efficacy. Applying the phospho-
flow technique to primary T cells, we examined phosphorylation of proteins that shape 
activation, proliferation, and differentiation of MUC1 tumor antigen-specific CD4 T cells within 
the first 24 hours post immunization as candidate biomarkers.  Previously, our lab has shown that 
a vaccine composed of a MUC1 peptide loaded on DC is more effective in eliciting T cell 
immunity than a vaccine composed of the same peptide plus adjuvant. Furthermore, both 
vaccines stimulate T cells more effectively in wildtype (WT) compared to MUC1.Tg mice.  We 
examined if signaling events downstream of the TCR or through various cell proliferation and 
survival pathways could predict differential potential of these two vaccines in two different hosts 
as early as 3, 6, 12, and 24 hours post immunization.  Signaling signatures obtained reflect 
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primarily differences between vaccines rather than between the hosts.  We demonstrate the 
feasibility of using this approach to evaluate a vaccine’s potential to elicit a desired response 
leading to better vaccine design. 
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1.0  INTRODUCTION 
The American Cancer Society expected over 1.6 million new cases of cancer to occur in 2012, 
and the mortality rate of those who suffer from the disease to be higher than 1,500 per day(2).  
For these patients, favorable prognostic outcome correlates with early detection of disease for a 
variety of reasons including smaller tumor burden and less immune suppression in an 
individual(3, 4). In efforts to better control the progression of cancer and eliminate tumors, 
oncology research is being directed at the discovery of mechanisms of disease, understanding the 
immune response to malignant cells, design and implementation of clinically beneficial 
therapeutic strategies, and preventing recurrence and even initial occurrence of cancer. Current 
therapeutic modalities are directed mainly at cellular processes that occur at an increased rate in 
cancer cells rather than specifically in malignant compared to healthy cells, resulting in a great 
deal of toxicity to the patient.  Advancements in the field of immunotherapy may provide tumor 
specific approaches that will alleviate much of the damage incurred by the surrounding healthy 
tissue. The importance of the immune response in contributing to control of cancer has been well 
illustrated. Evidence from both clinical trials and preclinical models have shown that the 
potential of a cell that has undergone malignant changes to develop into a tumor is contingent 
mainly upon the host response as well as the tumor microenvironment.  
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1.1 CANCER IMMUNOEDITING: THE INTERPLAY OF THE IMMUNE 
RESPONSE AND TUMOR EVOLUTION 
The relationship between the host immune system and tumor evolution is a dynamic process 
consisting of three levels of interplay: elimination, equilibrium, and escape.  Initial theories, 
proposed by Burnet and Thomas(5-7), were focused mainly on immunosurveillance and 
elimination of tumor cells by the immune system.  However, as our understanding of 
contributions of both innate and adaptive systems to tumor immunosurveillance advanced, so did 
our appreciation of the dynamic tumor microenvironment and the genetic instability of tumors 
that allow their evolution to hide from immune mechanisms of elimination.  Tumor cells that 
persist through initial immune mechanisms of identification and destruction are shaped by the 
immune mechanisms in their environment(8).  A state of equilibrium occurs, in which there is no 
clinical outgrowth of tumor yet the immune system isn’t successful at eliminating all tumor cells 
due to successful evasion by mutation.  During the equilibrium phase a number of things may 
happen.  The immune system may be able to eliminate the transformed cells, the system could 
remain in a state of permanent flux in which the tumor burden is neither eliminated nor able to 
progress to a clinically detectable level, or the transformed cells may progress to a clinically 
detectable tumor burden known as the phase of tumor escape. Tumor cells that persist, leading to 
tumor outgrowth under heavy immune pressure of a robust immune response, will be less 
immunogenic and better designed to continue immune evasion than those tumors that progress in 
immune compromised environments(9, 10).  This is important when considering therapeutic 
regimens to induce immune responses to existing tumor burden, especially metastases.  
 3 
1.1.1 Induction of the immune response  
Immunosurveillance begins with immature DC sampling antigen from the host environment.  
Peptide fragments, generated from antigen breakdown in the proteasomes, are presented and 
cross-presented in the context of MHC II and I to CD4 and CD8 T cells, respectively. At the time 
of antigen uptake a DC receives environmental signals of maturation, such as ATP, TLR ligands, 
and other danger signals. Appropriate maturation signals will result in upregulation of 
costimulation, such as B7 ligands and OX40L, and immunity promoting cytokine production, IL-
12, by DC.  However if DC encounter insufficient maturation signals, tolerance to the antigen 
presented will be promoted.  
Mature DC travel to the draining lymph node where initiation of T and B cell responses 
occur.  The induction of a robust protective T cell response requires 3 signals: stable TCR:MHC-
peptide complex interactions dictated largely by TCR affinity for the antigen, strong 
costimulation, and IL-12 cytokine production by the DC to promote Th1 development. DC with 
low or no levels of costimulation or producing IL-6 and TNF will induce more tolerant T and B 
cell responses. 
1.1.1.1 Protective immune responses 
Both the adaptive and innate responses contribute to protection from tumor formation, control of 
tumor growth, and prevention of disease progression. Mice deficient in the RAG2 gene, 
necessary for somatic rearrangement of antigen receptor gene segments and generation of T and 
B cells, are more susceptible to spontaneous and chemically induced tumor formation than 
wildtype counterparts(9). There is evidence that γδ T cells and αβ T cells play a role in immune 
mediated protection(11, 12). CD8 cytotoxic lymphocytes and CD4 effector T cells protect 
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against tumorigenesis by CTL perforin-mediated elimination of tumor cells(13, 14) and 
production of IFNγ(9).  IFNγ promotes Th1 development, CTL function, and induces cytotoxic 
functions of macrophages.  Preclinical studies have shown mice deficient in IFNγ are more 
susceptible to tumor induction(10, 15). Clinical studies have demonstrated that the presence of 
IFNγ producing T cells in the tumor environment is correlated to prolonged survival in 
patients(16, 17).    
Activation of NK and NKT cells diminishes the occurrence and growth of tumors(18-21).  
Tumor cells may induce the perforin and granzyme cytotoxic functions of these cells by 
recognition of missing self or tumor expression of ligands such as NKG2D and MICA/B(8). In 
addition, the production of Type I interferons by innate cells has been shown to be protective, in 
part by inducing activation of NK and NKT cells in responses to tumors(22, 23). 
1.1.1.2 Immune tolerance 
Tolerant responses, such as T cell anergy or induction of regulatory T cells, occur when DC are 
not sufficiently matured, lack costimulatory molecules, or increase regulatory molecules such as 
PDL1 while interacting with T cells. In addition, the production of TNF and IL-6 cytokines by 
DC can skew differentiation of CD4 T helper cells in the lymph node towards Th2 lineage cells 
that can produce IL-13 and promote growth of some tumor cells.   These T cells then home to the 
tumor bed and exert their immunosuppressive mechanisms within the tumor microenvironment.   
Preclinical mouse models demonstrate slowed tumor growth upon Treg depletion, 
establishing the immunosuppressive function of Treg on the immune response to tumors(24).  
Treg production of suppressive cytokines, IL-10 and TGFβ, can downregulate MHC and 
costimulatory molecules on DC, resulting in the priming of anergic T cells(25).  Treg also 
prevent effector T cell function directly by acting as an IL-2 sink, due to constituently high levels 
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of expression of IL-2 receptor on their cell surface, as well as direct killing mediated by 
granzyme and perforin(26). Treg have many additional mechanisms that can decrease effector T 
cell function, including the blocking of productive costimulatory interaction due to CTL4 
binding(27) and stimulation of IDO production, resulting in less tryptophan(28). 
1.1.2 Tumor evasion of the immune response 
The induction of tolerance by improper activation of antigen presenting cells and induction of 
anergic or immunosuppressive T cells are not the only ways that tumors avoid elimination.  
Tumors employ their own immune evasion techniques in order to avoid detection and deletion, 
allowing progression to clinically detectable levels.  Tumor cells can develop defects in HLA 
expression(29) and TAP activity(30), leading to deficiencies in antigen processing and 
presentation pathways, as well as downregulate the expression of costimulatory molecules in 
order to decrease activation of effector T cells. Expression of surface molecules that prevent 
activation or induce T cell apoptosis: CTLA-4, FasL, TRAIL, and PDL1 are often seen 
upregulated in tumors. Creation of an immunosuppressive microenvironment is furthered by the 
secretion of IL-10 and TGFβ cytokines(31), the production of IDO(32) and prostaglandins 
(PGE2), and the release of adenosine; together these promote Treg function while inhibiting 
effector T cell function. Some tumors have demonstrated the ability to evade the effector 
functions of T cells by developing defects in the IFNγ receptor signaling pathway(15), as well as 
the loss of targeted tumor associated antigens (TAA)(33). 
Furthermore, the tumor stroma secretes chemoattractants for the recruitment of 
suppressive immune cells: Treg, myeloid derived suppressor cells (MDSC), and anti-
inflammatory macrophages (M2)(34).  The activation of MDSC and M2 macrophages has been 
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shown in preclinical mouse models to correlate with increased tumor growth, disease 
progression, and the development of metastases.  MDSCs release arginase, nitric oxide synthase, 
and reactive oxygen species, suppressing CTL function(35). Macrophages have also been shown 
to suppress T cell function by increasing angiogenesis by release of matrix metalloprotease-9 
(MMP9)(36, 37). Treg mediate immune suppression as previously discussed.   
1.2 TUMOR IMMUNOTHERAPY 
There are two types of tumor immunotherapy: the transfer of passive immunity and the induction 
of active immunity.  Passive immunity is the transfer of antibodies or ex vivo generated CTL and 
effector cells into the host.  Active immunity is the induction of the host immune response 
through vaccination or other therapeutic intervention. Antibodies and vaccines can each function 
to control tumor progression; however, vaccination is advantageous in control of cancer before 
clinical disease starts.  
Most established FDA approved immune therapies (antibodies, recombinant cytokines, or 
adoptive T cell transfer) confer passive immunity to the patient.  These immunotherapeutic 
approaches have generated clinically relevant anti-tumor effects.   Antibodies can induce anti-
tumor immunity by activating complement-mediated cytotoxicity, direct killing of the tumor 
cells by antibody-dependent cellular cytotoxicity, or tumor specific delivery of radioactive 
elements or other cytotoxic substances(38, 39). The first attempt to induce active immunity in 
cancer patients via vaccination was conducted by William B. Coley.  While treating patients with 
sarcoma, Coley observed that those patients whose tumors were in remission had suffered from a 
severe bacterial infection of the skin.  He tried to recreate this event by injecting patients with a 
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combination of live or attenuated Streptococcus and Serratia marcescens(40, 41).  Coley’s 
attempts were met with little success. However, today we do mimic the danger signals these 
infections were producing to boost the immune response by our use of adjuvants with anti-tumor 
vaccines. 
Our understanding of immunotherapy has advanced significantly since Coley’s first 
experiments to induce a protective immune response, as is evident in our current understanding 
of vaccine design.  As we expand our knowledge of interactions of the immune response, the 
parameters we use as biomarkers of immunogenicity and correlates predictive of disease 
outcome are refined.  This leads to improvement in vaccine design and with it our ability to 
modulate the immune response. 
1.2.1 Tumor vaccines 
A tumor’s immunosuppressive microenvironment can impede the induction of a protective 
immune response as well as hinder and suppress the effector arm of the immune response. 
However, clinical evidence has demonstrated a strong association of the presence and type of T 
cells in a tumor to outcome of disease(16, 17).  Therefore, considerable effort has been placed on 
developing vaccines and other immunotherapies to boost pre-existing CTL activity, decrease 
mediators of suppression in the tumor microenvironment, and induce the activation and 
proliferation of new effector T cells.  There are three main places for therapeutic intervention in 
the immune response to tumors (Figure 1-1)(1). Manipulation of the antigen presenting function 
of DC is one place of improvement. This can include increasing antigen presentation and cross-
presentation, the maturation of DC with adjuvants, the quality of antigen (choice of antigen that 
is recognized with high affinity by T cell receptors), and the quantity of antigen processed.  The 
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second area is induction of a protective T and B cell response in the lymph node, including 
increasing costimulatory molecules and appropriate cytokine stimulus(1).  Lastly, decreasing 
immunosuppressive functions, whether mediated by the tumor or immune cells, is an area of 
great therapeutic importance in mounting a productive immune response(1).  Currently, most 
antibody therapy addresses immune suppression while vaccine therapy focuses on induction of 
an immune response.   Tumor vaccines are advantageous in that they not only induce effector 
responses but long term memory responses that are important in disease-free patient survival. 
 
Figure 1-1.  Generation and regulation of antitumor immunity. 
 
 Vaccines can be designed as either prophylactic or therapeutic regimens.  Evidence 
suggests that a prophylactic vaccine would induce a more robust immune response. It has been 
Understanding the events in generating and regulating antitumor immunity suggests at least three sites for 
therapeutic intervention:  promoting the antigen presentation functions of dendritic cells, promoting the 
protective T cell responses and overcoming immunosuppression in the tumour bed.  From Mellman I., Coukos 
G., and Dranoff, G.  2011. Nature. 480: 480-489. (1) 
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established that the best protection against infectious disease occurs before the host encounters 
the infectious agent, and reasonably the same would hold true against cancerous cells.  Initiating 
an immune response before tumorigenesis, would allow for the identification and elimination of 
the neoplastic cells before the tumor burden becomes large, thus preventing much of the 
immunosuppressive microenvironment associated with established tumor beds(1).  In addition, 
the immune response may be weakened by radiation and/or chemotherapy treatments.  However, 
the vast majority of vaccines approved for anti-tumor therapy in clinical trials are therapeutic and 
will remain as such until safety and efficacy are proven.  The basis of their therapeutic value lies 
in the ability to stimulate pre-existing CD4 and CD8 tumor specific cells residing in the 
tumors(1).  
Although the stage of the immune response targeted as well as the state of the immune 
response (whether given prophylactic or therapeutic treatment) play very important roles in the 
immunogenicity of a vaccine, vaccine design also plays a major role.  There are three major 
facets that comprise vaccine design: route of administration, choice of adjuvant, and choice of 
antigen(42).  The augmentation of a more local, versus systemic, response can vary dependent on 
route of administration, and may affect the ability to mount an effective primary and memory 
response.  The choice of adjuvant is of equal if not greater importance.  A suitable adjuvant can 
vary widely, from GMCSF or TLR ligands which induce strong maturation signals in DC, 
cytokines such as IL-2 to promote T cell activation, vaccine virus vectors to induce strong 
immune responses to viral products, coupling to monoclonal antibodies for more specific 
targeting or to induce specific signaling, matured DC themselves, and many others. Common to 
all these is the ability to induce protective T cell responses, often through the strong maturation 
of DC.  Lastly, but very important in the manipulation of the immune response is the choice of 
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antigen.  The immune response is dependent on the ability of a DC to process the antigen, 
present the antigen and costimulatory molecules, and the affinity of the TCR for the antigen 
presented.  As with adjuvants, there are numerous possible cancer-associated antigens that may 
stimulate an immune response.  Suitable antigen candidates for tumor vaccines must not only 
elicit a strong immune response, but must meet certain criteria in the host response to ensure 
safety as well as criteria in tumors to ensure widespread applicability.  It is important for 
immunogenicity in patients that the antigen not be subjected to self-tolerance and imperative for 
safety that intensifying the immune response to the antigen does not lead to autoimmunity.  The 
widespread and stable expression of an antigen on a variety of tumors, throughout progression of 
disease, is an important factor in the ability of the immune response to mount and eliminate 
cancerous cells. A favorable antigen would be one that is essential for persistence of the tumor, 
preventing the possibility of immunoediting(8). 
1.2.2 Tumor antigens 
1.2.2.1 Tumor specific antigens 
Some tumors may express mutated or viral genes that are not expressed in normal cells.  There 
are several known viruses associated with tumorigenesis: Human papilloma virus (HPV), Merkel 
cell polyomavirus (MCV), Epstein Barr virus (EBV), Hepatitis B virus (HBV), Hepatitis C virus 
(HCV), human T lymphotrophic virus 1 (HTLV-1) and type 2 (HTLV-2), and human herpes 
virus 8 (HHV8)(34, 43).  Viral proteins are processed and presented in MHC on the surface of 
the transformed cells, however sometimes not in an adequate concentration to mount an effective 
T cell response.  These tumor specific proteins are very good candidates for vaccines in that a 
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more robust T cell response could provide better elimination of infected cells, the viral antigens 
are not subject to self-tolerance, and there is no risk of autoimmune disease.   
1.2.2.2 Tumor-associated antigens (TAA) 
Tumor-associated antigens (TAA) comprise the majority of tumor antigens.  These are self-
antigens that are expressed on healthy cells, but are aberrantly expressed or have undergone 
posttranslational modifications in tumor cells.  For instance, the well-known molecules 
HER2/neu and Cyclin B1 are overexpressed in breast cancer. The aberrant glycosylation and 
overexpression are well characterized in the abnormal tumor form of the protein MUC1 in a 
variety of cancers.  Other tumor antigens have been identified and are being used as biomarkers 
of disease.  These antigens may be subject to central or peripheral tolerance in order to prevent 
damage to healthy tissues. Several of these TAAs have been well characterized and are in 
vaccine development in clinical trials. 
Human epidermal growth factor receptor 2 (HER2/neu) is a transmembrane glycoprotein 
expressed at low levels on the surface of normal cells.  This receptor tyrosine kinase is part of the 
epidermal growth factor family and is normally involved in regulation of the cell cycle.  
Overexpression of HER2/neu is seen a variety of adenocarcinomas including that of breast, 
ovarian, and uterine tissues(44), is associated with aggressive disease and has been indicated to 
play a role in disease progression.  Detection of aberrant expression of HER2/neu in patients is 
correlated with poor prognosis and poor survival(45-47). 
Cyclin B1 is another example of a self-antigen that can be recognized by the immune 
system after abnormal expression upon malignant changes in a cell.  Normally cyclin B1 is 
expressed transiently in small amount in the nucleus of dividing cells to promote transition from 
the G2 to M phase of the cell cycle.  A constitutive expression of cyclin B1 leading to its 
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detection in the cytoplasm has been seen in tumor cells as a result of dysfunction of the well-
known tumor suppressor, p53(48, 49).   This overexpression and cytoplasmic localization allows 
for initiation of an immune response that wouldn’t normally occur.   
Mucin1 (MUC1) is a transmembrane glycoprotein expressed on the apical surface of 
secretory epithelial cells.  Its extracellular domain is comprised largely of a VNTR (variable 
number tandem repeat) region of 20 amino acids repeated in tandem 20-120 times.  Two serine 
and three threonine residues per 20 amino acid sequence binds highly glycosylated o-linked 
carbohydrates.  Upon malignant transformation, MUC1 loses polarity and is overexpressed.  The 
VNTR region becomes hypoglycosylated and the carbohydrate chains present are less branched 
with only one or two sugars (Figure 1-2).  This exposes the peptide backbone for antibody 
recognition as well as resulting in differences in the way the molecule is processed for antigen 
presentation.   
 
Figure 1-2.  Normal and abnormal MUC1 
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In healthy normal epithelia, MUC1 is highly glycosylated and expressed on the apical surface.  When a cell 
undergoes neoplastic events, MUC1 becomes hypoglycosylated, loses polarity, and is overexpressed.  Figure 
courtesy of Pamela Beatty. 
 
1.2.2.3 Tissue-restricted antigens 
Malignant cells can also express proteins that are usually restricted, in healthy cells, to 
expression in a specific type of tissue, a specific lineage of cells, or during a particular phase of 
development, such as during embryonic development. Frequently these antigens are restricted to 
sites of immune privilege, such as the testis or placenta(50).  These otherwise tissue-restricted 
antigens are expressed in many adenocarcinomas, melanomas, and a wide variety of other 
cancers.  For instance, numerous adenocarcinomas express carcinoembryonic antigen (CEA), 
normally only expressed or secreted during fetal development(51, 52). Another example, NY-
ESO-1 is normally restricted to expression in germ cells and trophoblasts; however this testis 
antigen is expressed in a large array of tumors(53).  Melanomas often express cancer/testis 
antigens such as MAGE and gp100.  These otherwise tissue-restricted antigens are thought to 
have considerably less risk of inducing autoimmunity due to their normal expression in immune 
privileged sites, making them attractive antigens for tumor vaccines in clinical trials(54).   
1.2.3 Current status of approved immunotherapies to treat cancer 
Despite each of their individual expression on a large percentage and a broad range of 
malignancies, there are few Food and Drug Administration (FDA) approved treatments directed 
against tumor antigens. Currently, there are several clinically effective, FDA-approved,  
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monoclonal antibody therapies against proteins associated with cancer, including growth factor 
receptors, B cell antigens, a T cell regulatory molecule, and tumor antigens(1, 55).  Antibody 
against the negative immune regulator CTLA-4 has shown promise for activation and 
proliferation of pre-existing tumor specific T cells.. Although there has been evidence of 
significant levels of autoimmunity in some patients(56), disease stabilization and a distinct 
increase in survival have been seen in a subset of metastatic melanoma patients treated with anti-
CTLA4 in multiple clinical trials(57, 58).  Another promising therapy, Herceptin® 
(trastuzumab), is a monoclonal antibody that targets the HER2/neu receptor, a tumor-associated 
antigen.  Herceptin is being used to control HER2/neu positive tumor growth after 
chemotherapy, reduce disease recurrence, and improve survival in breast cancer patients (59-61).  
In addition to antibodies, there are also several FDA approved recombinant cytokine therapies, 
such as IL-2 and interferon-α, demonstrating some clinical benefit for cancer patients. 
Cancer immunotherapy has seen some recent breakthroughs with two FDA approved 
vaccines.  The FDA has approved the first prophylactic cancer vaccine to a human papilloma 
virus (HPV) antigen.  A multivalent L1-virus like particle vaccine to the L1 capsid protein of 
HPV has been shown to be effective in prevention of infection, including type 16 and 18, that is 
associated with cervical cancer(62-64).   This vaccine could prevent the 70% of cervical cancer 
associated with HPV infection. Of late, the FDA approved the first active therapeutic for late 
stage cancer.  Provenge® (sipuleucel-T) is a cellular therapy based on an individual patient’s 
antigen presenting cells harvested from peripheral blood mononuclear cells (PBMC) and 
incubated with a fusion protein of GMCSF and the TAA prostatic acid phosphatase (PAP).  
Clinical trials reported no evidence of tumor control or stable disease by standard parameter of 
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tumor growth; however patients receiving the treatment had an increased median survival time of 
4 months(65).  
 Recently, there has been a push to develop effective vaccines targeted against non-viral 
tumor-associated antigens, with many treatments showing promise in clinical trials.   There are 
countless potential TAA to be used as immunotherapeutic targets, with new TAAs still being 
discovered. In the attempt to accelerate the development of a successful cancer vaccine targeting 
these antigens, the National Cancer Institute (NCI) and experts in the field have developed 
weighted criteria to prioritize research on tumor-associated antigens.  Several promising 
candidates have been identified and among the highest in priority is the antigen MUC1(66). 
1.3 MUC1 
1.3.1 Functions of MUC1 
Mucins, including MUC1, serve as lubricants and physical barriers for epithelial cells for 
protection from infectious microbes. Normally, MUC1 is located on the luminal surface, 
initiating signaling in response to environmental stimuli such as changes in pH or physical 
stimulation. However, loss of polarity in a cell leads to differential expression and glycosylation 
of these molecules and changes in their functions as well. On a cellular and molecular level the 
abnormal form of MUC1 has been implicated in multiple facets of tumorigenesis, tumor growth, 
and survival.  On a tumor cell, the abnormal form of MUC1 is no longer segregated from 
receptor tyrosine kinases or other receptors usually expressed on the basal surface of the cell.  
Abnormal MUC1 has been shown to serve as an oncogene by modulating the activation of 
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multiple intracellular signaling molecules (67, 68).  It has been found to bind chaperone 
molecules and increase activation of Ras/Raf pathway signaling downstream of epidermal 
growth factor receptor  (EGFR) in an EGF-dependent manner(69).   The tumor form of MUC1 
can bind NF-κB blocking association with its inhibitor IκBα leading to activation of NF-κB 
mediated transcription(70, 71).  In addition, abnormal MUC1 can prevent apoptosis of cancer 
cells by modulating activity of tumor suppressor genes, such as p53, by binding regulatory 
domains affecting transcription(72, 73).   
The tumor form of MUC1 promotes metastasis of tumor cells in several ways.  
Intracellular junctions are created by E-cadherin binding with members of the catenin family of 
proteins.  MUC1 causes destabilization of intracellular junctions by by binding and sequestering 
β-catenin, thereby disrupting the association of β -catenin and E cadherin(74).  This stabilization 
of β -catenin in the cytoplasm weakens cell adhesion and promotes activation of the Wnt 
signaling pathway which is associated with tumor growth(75). In addition, the VNTR region of 
abnormal MUC1 can serve as a ligand to intracellular adhesion molecule 1(ICAM-1) and may 
play a role in metastasis(76). 
The hypoglycosylated form of MUC1 has roles in various immune functions. It serves as 
a chemoattractant for DCs, providing maturation stimuli upon their arrival(77).  The maturation 
signals encountered in the MUC1 tumor environment promotes the generation of  IL-6 and TNF 
producing DC that fail to make IL-12.  Priming of naïve T cells by these DC skews T cell 
differentiation towards IL-5 and IL-13 producing Th2 effector cells(77).  IL-13 can activate NKT 
cell mediated suppression of immunosurveillance as well as promote tumor growth directly(78). 
The role MUC1 plays in cancer as well as its TAA properties, make MUC1 an attractive 
candidate and target for immunotherapy as well as other novel therapeutic interventions.  Here, 
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our interest in MUC1 is solely as a tumor-associated antigen that can be targeted to enhance 
protective immunity against tumors.  
1.3.2 DC processing of MUC1 
Over expression and hypoglycosylation are important in initiating a different immune response 
to self versus abnormal self.  The normal heavily glycosylated and abnormally hypoglycosylated 
forms of MUC1 can both be readily taken up by dendritic cells.  However, heavily glycosylated 
proteins are not transported into late endosomes for antigen processing but are retained for long 
periods of time in the early endosome without processing(79).  As a result there is very little 
presentation of processed antigen from the heavily glycosylated form on surface MHC II or I.  
However, abnormal MUC1 molecules are trafficked through antigen processing compartments 
for presentation in Class I and II molecules on the surface(79).  Degradation and processing of 
abnormal MUC1 yields new peptides and glycopeptides capable of eliciting a T cell response.  
The degree of the CTL response has been shown to be inversely correlated to the degree of 
glycosylation of the molecule(80). 
1.3.3 Immune response to abnormal MUC1 
Expression of abnormal MUC1 has been established in many adenocarcinomas including those 
originating in the breast, colon, pancreas, ovaries and other tissues(81), as well as in non-small 
cell lung carcinomas (NSCLC)(82), multiple myelomas(83), and head and neck squamous cell 
carcinomas (HNSCC)(84).  Patients with MUC1 positive tumors have been reported to exhibit a 
weak immune response to MUC1.  Low titers of MUC1 reactive antibodies, predominately of the 
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IgM isotype can be detected in their sera(85, 86).  Low frequencies of CD8 CTL that are specific 
to the MUC1 polypeptide core can also be found(87-89).  However, in vitro expansion of these 
CTL have shown that the majority of the response is MHC unrestricted(89, 90) with only a few 
MHC-restricted epitopes identified(91, 92).  In addition, there has been little evidence of a 
MUC1-specific helper T cell response in cancer patients.  The lack of a CD4 helper T cell 
response is a likely reason for the weak CTL response and absence of isotype switching of 
antibodies to IgG in these patients.  Hiltbold et al showed that MUC1 specific CD4 T cells were 
not being deleted and consequentially not subject to central tolerance(93).    MUC1-specific CD4 
T cells could be generated from PBMC of healthy controls in vitro in response to MUC1 peptide.  
These observations suggest that eliciting a robust CD4 T cell response may lead to the generation 
of therapeutically relevant levels of CTL and antibodies. 
The immune response to aberrant expression and hypoglycosylation is clinically relevant.  
Detection of abnormal MUC1 on tissue or in circulation is a strong correlate with poor prognosis 
and poor patient survival(94, 95).  Conversely, detection of naturally occurring MUC1-specific 
antibodies in the sera is indicative of a more favorable prognosis.  MUC1-specific antibodies in 
breast, pancreatic, and gastric cancer patients were correlated to prolonged survival and reduced 
incidence of metastasis(96-98).  The existence of circulating MUC1 antibodies has even been 
shown to be protective, lowering the risk of cancer(99).   
1.3.4 MUC1 vaccines in clinical trials 
The protection afforded by natural induction of MUC1-specific antibodies in conjunction with 
the known deficiencies in the immune response to MUC1, suggest it would be advantageous to 
boost the endogenous antibody and T cell response through vaccination.  Vaccine trials for 
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numerous TAAs, including MUC1, are ongoing in the clinic. These trials vary vaccine 
formulation (including peptides and adjuvants), modes of delivery, and vaccination schedules in 
efforts to create the best possible therapy providing a combination of low toxicity and high 
immunogenicity.  Many clinical trials testing MUC1 vaccines have been conducted in patients 
suffering from breast, pancreatic, lung, prostrate, ovarian, and renal cancer in the past two 
decades(27, 81).    
Pioneering the field with the first synthetic TAA vaccine, a Phase I trial of a MUC1 
vaccine began in 1993(100).  Sixty-three late stage breast, colon, and pancreatic cancer patients 
were enrolled post chemotherapy treatment to receive a vaccine of MUC1 105 amino acid 
peptide admixed with BCG. Importantly, the vaccine showed no signs of treatment related 
toxicity or development of autoimmunity.  Seven of 22 patients tested were found to have a 
small increase in MUC1 specific CTL, however there was no clinical benefit or memory 
response observed. This study helped to establish the safety of the vaccine but potential to 
stimulate a strong response to MUC1 was difficult to assess in patients with impaired immune 
function and advanced disease.  
In 2004, a Phase I trial of sixteen pancreatic cancer patients addressed not only safety but 
also immunogenicity in a group having no chemotherapeutic intervention.  After tumor resection, 
patients were treated with MUC1 100mer (a 100 amino acid sequence from the VNTR region) 
vaccine admixed with SB-AS2 adjuvant (monophosphoryl A, purified saponin and an oil-water 
immersion)(101).  These patients exhibited a low but measurable increase in humoral response 
with five patients exhibiting MUC1 IgG antibodies, and an increase in CD8 T cells with no 
autoimmunity detected.  A 32 and 61 month follow up proved two of fifteen patients to be free of 
disease.  Although the elicited response was not as robust or therapeutic as desired, the 
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improvement seen was further evidence of a correlation of immune state and the ability of a 
vaccine to impact development of the immune response. 
Several MUC1 vaccine trials in ovarian cancer have also shown safety of the vaccines 
and evidence of humoral and cellular responses to MUC1(102-104).  In addition, MUC1 
vaccines either conjugated to keyhole limpet hemocyanin or delivered in a vaccina virus were 
well tolerated, and antibody and CTL responses were attained in clinical trials of patients 
suffering from breast cancer(105-108).  Evidence of clinical benefit of MUC1 immunotherapy 
has been seen in three renal cancer trials, in which not only was no toxicity associated with 
treatment and immunogenicity to MUC1 induced, there was some success achieving stable 
disease in multiple patients(109-111).  Promising results have also been achieved in two Phase II 
clinical trials using MUC1 peptide in a liposome vector (BLP25) admixed with a 
monophosphoryl lipid A adjuvant(112, 113) and a recombinant vaccina virus as a MUC1 vehicle 
with IL-2(114, 115) to treat non-small cell lung carcinomas.  Patients vaccinated with MUC1 had 
prolonged survival compared to non-vaccinated groups.  Phase III large randomized trials are 
now underway for both MUC1 vaccines. Interestingly, only two of the sixteen patients exhibiting 
prolonged survival demonstrated an expansion of CTL as a predictor of immunogenicity.  This 
underscores the importance of having reliable correlatives of protection while assessing vaccine 
efficacy that are both predictive of immunogenicity and outcome of disease. 
There are other clinical trials that demonstrate the need for better biomarkers and 
parameters of vaccine efficacy.  A Phase I/II trial of MUC1 vaccine efficacy in pancreatic 
patients displayed promising yet unclear results initially.  Twelve pancreatic patients were 
treated with a MUC1 peptide loaded DC vaccine after resection of their tumors.  The vaccine 
proved to be safe however due to an increase in the presence of Treg the ability to effectively 
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prime a protective T cell responsive was not distinguishable.  Interestingly, long term assessment 
four years post vaccination revealed four of twelve patients without reoccurrence of 
disease(116).  This study demonstrated a need for improved parameters of detection of vaccine 
efficacy that will correlate early immune responses with later immune function in controlling 
disease. 
As demonstrated by the above studies, the use of TAA vaccines as a therapeutic measure 
to control cancer can lead to underestimation of the true capacity of a vaccine to induce a 
protective immune response.  Prevention of infectious disease with the use of vaccines as a 
prophylactic regimen has proven to be quite successful(117).  The same will most likely hold 
true for cancer, where priming can happen in an immune competent environment, leading to a 
more efficient immune response when cancer first arises and the tumor burden will be low.  The 
first prophylactic cancer vaccine trial that used tumor antigens instead of viral antigens was 
recently conducted(118).  Patients with premalignant colon polyps, at a high risk for developing 
colon cancer, were enrolled and given MUC1 100mer peptide admixed with Hiltonol (a TLR 3 
ligand known as poly-ICLC). Patients exhibited high levels of IgG production (17/39) with a 
robust memory response upon boost.  The lack of a humoral response (22/39) was correlated 
with a high frequency of myeloid derived suppressor cells (MDSC).  This data suggests that a 
more robust immune response is generated in the prophylactic phase and in environments in 
which immune suppression is low leading to more effective prevention and control of disease.  
Determining the efficacy of a vaccine used as a prophylatically requires larger test groups and a 
long duration of study, illustrating the need for early detection of immunogenicity parameters 
that are predictive of disease outcome. 
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1.4 PRECLINICAL MODELS 
Prior to clinical trials in patients, treatment regimens must pass through extensive rigorous 
investigations in multiple preclinical models.  Preclinical models allow for an examination of 
treatment toxicity, several parameters of efficacy, and disease outcome, often more thoroughly 
then can be achieved in clinical trials.  The most widely used preclinical model is the mouse.  
The advent of genetic engineering has allowed for the generation of many strains of specialized 
mice to hone in on specific functions of molecules, modulation of specific cells and entire 
systems, as well as both focused and systemic effects of treatments such as vaccination.  
These mouse models have been the route of discovery for immune functions, key to 
understanding interactions in the immune response, and the ability to examine the effects of 
manipulation of components of the immune response. 
1.4.1 MUC1 Transgenic Mice 
A genetically engineered transgenic mouse has been developed to express the human form of 
Mucin1 (MUC1) under the control of its endogenous promoter(119).  Therefore, expression is 
biologically relevant both quantitatively in the amount of expression and qualitatively in its 
natural expression pattern.  The MUC1 transgenic (MUC1.Tg) mouse model is well 
characterized as a model for the study of tumor-associated antigens in cancer(120). MUC1.Tg 
mice have lead to insights in immune cell functions and interactions as well as the host response 
to “abnormal self.”   Vaccination with MUC1 has shown the ability of MUC1.Tg mice to 
generate MUC1-specific immunity with no indication of autoimmunity(121).  Given as a 
prophylaxis, MUC1 vaccine induces a protective immune response against MUC1 positive tumor 
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formation, and can induce tumor regression as a therapeutic regimen.  In addition, differences in 
MUC1 vaccine design lead to differences in the immune response within the MUC1.Tg 
mouse(121).  Importantly, the effectiveness of the MUC1-specific immune response to the tumor 
form of MUC1 in the MUC1.Tg mouse (where it is perceived as an abnormal version of an 
endogenously expressed molecule) is not as robust as compared to an environment in which it is 
not endogenously expressed and perceived as foreign (as in wildtype mice)(122, 123).  The 
dampened immune response has been attributed to deficiencies in the CD4 T cell response(124).  
There is less of a proliferative response and lower production of IFNγ exhibited by MUC1-
specific CD4 T cells in response to MUC1 antigen in MUC1.Tg mice then in their wildtype 
counterparts(122, 123).  These findings suggest an altered detection of abnormal self versus 
foreign self.    
The MUC1.Tg mouse model system enables dissection of a productive immune response 
compared to a more tolerant immune reaction induced by antigen specific responses based on 
environment. This enables us to investigate early antigen-specific T cell responses that result in 
the establishment of immunity or tolerance.  We use the well-established flow cytometry 
technique of phospho-flow to examine the activation of early MUC1-specific T cell signaling 
events to MUC1 antigen in MUC1.Tg and WT mice.   
1.5 PHOSPHO-FLOW 
Phospho-flow is a technique that allows for the multiparameter analysis of single cells, which 
can be adapted for high-throughput screening ideal for clinical studies(125-129).  The ability of 
this technique to analyze single cells in heterogeneous populations can provide insight into the 
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signaling pathways activated, the relationship between networks of signaling, and the signaling 
profiles could result in correlation to therapeutic efficacy, disease progression, and clinical 
outcome(129).  Phospho-flow has been used to identify alterations in the signaling profile of 
patients with acute myeloid leukemia in response to cytokine stimulation, and demonstrated a 
deficiency in STAT1 signaling in response to IFNγ stimulation(130).  Knowledge of alterations 
in the ability of cancer patients to respond to certain stimuli could lead to development of new 
therapeutics as well as alterations in individual treatment strategies(129).  To date, phospho-flow 
has been employed experimentally to examine alterations in cellular signaling in individuals 
suffering from late stage cancer, autoimmune disorders, and infection(131, 132).  In addition, 
there has been some initiative to use phospho-flow to predict patient response to therapy(133). 
We propose that identification of the activated signaling pathways in T cells after 
therapeutic treatment will be predictive of the immune response that ensues.  We have identified 
several ‘phospho-fingerprint’ candidates based on their known central role in signaling pathways 
related to T cell activation, differentiation, proliferation, and survival (Table 1). The quality 
(targets phosphorylated), quantity (the numbers of cells expressing the phosphorylated targets), 
and temporality (the time and sequence in which signaling pathways are activated) may all 
determine if a signaling ‘fingerprint’ is correlated to the induction of a protective or a tolerant 
response. 
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Table 1.  Candidates for T cell ‘phospho-fingerprint’ in response to immunization 
 
1.6 INTRACELLULAR T CELL SIGNALING 
Environmental cues, such as cytokines and TLR ligands, as well as interactions between cells 
activate intracellular signaling pathways in T cells inducing and shaping their response.  The 
signaling pathways activated determine the magnitude and duration of the T cell response.  The 
signaling controlling cellular processes is a complex intricate network with many components of 
regulation. The signaling molecules we chose to examine (Table 1) are involved in T cell 
activation after antigen recognition, differentiation of T helper cells, and cell survival and 
proliferation.  Here, we discuss some of the predominant effects of phosphorylation of the 
selected targets. 
The initial T cell response to antigenic stimulation consists of two main components: T 
cell receptor (TCR) signaling after peptide-MHC recognition and costimulatory signaling.  TCR 
binding to the peptide-MHC complex induces the phosphorylation of ZAP70 and Lck leading to 
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functionally active kinases(134). Signaling through the CD28 costimulatory receptor can lead to 
the up-regulation of expression of other costimulatory molecules such as CD40L and 
OX40(135).  The activation of costimulatory signaling can affect the amplitude and persistence 
of both ZAP70 and Lck phosphorylation, prolonging their activation.  The activation of ZAP70 
and Lck leads to further phosphorylation via multiple signaling cascades leading to T cell 
activation and proliferation. 
The microenvironment of a CD4 T cell dictates the network of signaling pathways that 
function together to determine helper T cell differentiation and fate(136).  There are multiple 
subsets of CD4 T helper cells including Th1, Th2, Th17, and regulatory T cells.  Intracellular 
signaling through the JAK/STAT pathways downstream of cytokine receptors is crucial to the 
initiation and maintenance of genes responsible for T cell differentiation(137, 138).  Binding of 
IFNγ and IL-12 to their respective cell surface receptors signal through STAT1 and STAT4 
respectively, skewing T helper cells to mainly a Th1 phenotype responsible for the clearance of 
intracellular pathogens and cellular immunity(137).  The transcription factor, Tbet, is also 
associated with the differentiation and maintenance of the Th1 phenotype.   However, signaling 
through the IL-4 receptor activates STAT6 that in conjunction with the transcription factor 
GATA3 skews T cell differentiation towards Th2 phenotype(139, 140).  Th2 immunity is 
associated with allergy, clearance of extracellular pathogens, and induction of humoral 
immunity.  The differentiation of the Th17 subset is associated with IL-6, IL-23, and IL-21 
receptor signaling through STAT3(141-143).  Th17 cells play a role in autoimmunity, tissue 
inflammation, and clearance of extracellular pathogens.  In addition, activation of STAT5 
through the IL-2 receptor is associated not only with transient T cell activation but with the 
development of regulatory T cells(144).  STAT5 directly binds and activates the transcription 
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factor FOXP3 that regulates Treg development(145).  On the other hand, the early activation of 
S6 is inversely correlated to Treg development.  
There are multiple avenues that lead to cellular proliferation and survival. G protein-
coupled receptors (GPCRs), ion channels, growth factors, receptor tyrosine kinases (RTKs), and 
integrins can activate ERK1/2 signaling through the RAS/Raf pathways leading to progression of 
T cell growth and proliferation(146).  Activation of receptors for integrins, RTKs, cytokines 
(such as IL-7), and the TCR can result in the downstream activation of Akt signaling through the 
PI3K signaling pathway(146). Activation of Akt leads to a number of cellular activities such as 
increased protein synthesis (such as the synthesis of the anti-apoptotic protein BCL-2), survival, 
and proliferation(147).  In addition, GPCRs, growth factors, DNA damage, oxidative stress, and 
inflammatory cytokines can trigger the p38MAPK signaling pathways that result in cytokine 
production, T cell anergy, and apoptosis(148). 
1.7 STATEMENT OF PURPOSE 
As previously discussed, immunotherapy is used widely in the clinic but its beneficial effects are 
realized long-term.  Cancer vaccines are a long-standing interest of our laboratory. Most recently 
we have focused on developing prophylactic vaccines based on the tumor associated antigen 
(TAA) MUC1 for individuals with premalignant lesions or other diagnoses that put them at high 
risk for developing MUC1 positive cancer.  This requires development of biomarkers to be 
measured early after vaccination that could predict future anti-tumor efficacy.  Currently no such 
biomarkers exist for any therapeutic or prophylactic cancer vaccine.  Our specific goal is to 
identify biomarkers predictive of the MUC1 vaccine efficacy that could also be generalized to 
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other TAA based vaccines. We hypothesize that the phospho-flow technique will allow us to 
detect early intracellular signaling profiles that serve as a hallmark of antigen-specific T cell 
activation may be used as biomarkers for future anti-cancer therapeutic efficacy.  
MUC1, a highly glycosylated molecule on ductal epithelia, is aberrantly 
hypoglycosylated, overexpressed, and immunogenic in its tumor form.  Our lab has previously 
found that both endogenous T cells as well as adoptively transferred TCR transgenic T cells 
specific for the MUC1 peptide, have reduced responses (e.g. proliferation and interferon-γ 
production) to MUC1 peptide vaccination in MUC1.Tg mice compared to wildtype mice. We 
used this model system to examine early intracellular signaling events in CD4 T cells during 
priming for effector cell generation, in response to two different MUC1 vaccines in MUC1.Tg 
versus WT mice, to define potential differences that can be correlated with differences in 
functional outcome. The ability to alter these signaling profiles by varying vaccine design is 
examined as well.  The work was performed within two specific aims:  
 
Specific Aim I (Chapter 2): Optimize the phospho-flow technique for peak detection of 
phosphorylation in MUC1-specific T cells in vivo responding to stimulation by MUC1 
vaccines. 
Prior to the determination of whether T cell signaling was suitable as a parameter to evaluate 
therapeutic efficacy, the limitations and successes of using the technique to evaluate antigen-
specific signaling initiated in vivo needed to be assessed.  We demonstrated the limitations of the 
technique as originally published, and optimized it to detect antigen-specific signaling in  in vivo 
stimulated  T cells.  
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Specific Aim II (Chapter 3): Examine intracellular signaling profiles in CD4 T cells in 
MUC1.Tg versus WT mice during priming for effector cell generation in response to a 
MUC1 peptide vaccine, and investigate how changes in vaccine design can modulate the 
signaling response. 
MUC1.Tg and WT mice were immunized with soluble adjuvant-based and DC-based MUC1 
vaccines.  The activation of intracellular signaling pathways (downstream of TCR, 
CD28/CD40L, and cytokine receptors) in CD4 TCR transgenic T cells (MUC1 specific and 
OVA specific as controls) was assessed by phospho-flow cytometry, in addition to flow 
cytometric analysis of the cell surface phenotype. We demonstrated that there were detectable 
differences in the T cell signaling profiles; to a large degree in response to vaccine design and to 
a lesser degree between MUC1.Tg and WT mice, but especially dependent on vaccine designs 
within the first 24 hours post immunization.  
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2.0  OPTIMIZATION OF THE PHOSPHO-FLOW TECHNIQUE FOR ANALYSIS OF 
PRIMARY CD4 T CELL SIGNALING POST IN VIVO STIMULATION 
2.1 INTRODUCTION 
Biomarkers of cancer are used to evaluate treatment efficacy, disease progression and 
reoccurrence, and to define disease stage.  Many of the existent biomarkers have low diagnostic 
sensitivity and specificity, and few known markers have predictive power of therapeutic 
responses.  Early elucidation of the effect an experimental vaccine strategy has on priming the 
immune response, whether in animal models or clinical trials, is of extreme importance.  At 
present, long lengths of time are required to accurately predict the immunogenicity of a vaccine.   
Therefore, new improved cancer biomarkers are sought after. The advent of new technology or 
novel development of existing technology often leads to advancements in biomarkers. Phospho-
flow is one such development in the field of flow cytometry that shows promise(149). 
 We proposed that in addition to published applications of this technique that 
mostly involved homogenous activation of cell lines or very strong stimuli to primary cells, 
phospho-flow could be used to measure very early activation of T cell signaling networks after 
immunization creating T cell signaling profiles that predict the outcome of the immune response, 
serving as a biomarker for vaccine efficacy. The sensitivity and reproducibility of the phospho-
flow technique to analyze the phosphorylative response of single cells within a population to 
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stimulation has been well established in vitro(125-128).  These responses are prompted by strong 
external stimuli such as cytokines, PMA/IONO, PHA, or pervanadate treatments.  Furthermore, 
signaling differences that have been demonstrated between signaling and healthy states are not 
seen at basal states of phosphorylation, and can be deciphered only in the presence of activating 
stimuli(130, 150).  Moreover, measuring signals in vitro has the distinct advantage of 
simultaneous stimulation of a large group of cells resulting in a known measurable and collective 
peak in the response(151, 152).  To our knowledge, the use of this technique to measure 
signaling events of cells stimulated in vivo until now has been confined to situations where the 
stimulus is a bolus of adjuvant or cytokine(153), antibody(154), TLR ligands(155), vaccine virus 
infection(155), or a soluble peptide that binds directly to the MHC(156, 157).  
Many hurdles exist that may require optimization of the phospho-flow technique in order 
for it to be an effective means of detecting phosphorylation signatures in an antigen-specific 
response to immunization.  The antigen-specific activation we wished to measure would 
presumably be a much weaker response then those illustrated above for many reasons.  Antigen 
processing time, the time until the vaccine reaches the lymphoid organ, and the time it takes for a 
stable TCR:MHC synapse to form between an antigen-specific T cell and mature antigen 
presenting DC are all variable; consequentially the peak of the response will be difficult to 
detect.  Furthermore, at such early timepoints many activation markers are not yet upregulated so 
T cells that have not yet been primed may dilute the signal.  In addition, the route of 
administration may result in signaling differences due to timing and specific conditions within 
the lymphoid organ in which it is primed.  Moreover, differences in vaccine design, the adjuvant 
present, and variability between the individual mice may affect signal to background ratio.  All 
of these factors need to be taken into consideration, and the technique optimized to create the 
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most sensitive detection of phosphorylation. Here, we examine the intensity and sensitivity of 
detection of intracellular phosphorylation by variations in the basic phospho-flow protocol and 
alterations in assay design in in vitro and ex vivo assays in order to optimize the phospho-flow 
technique to optimize the measurement of intracellular signaling induced in primary T cells after 
stimulation in vivo.  
2.2 METHODS 
2.2.1 Mice 
C57BL/6 (WT), BALB/c, and C57BL/6-Tg (TcraTcrb)42SCbn/J (OT-II TCR-transgenic) mice 
purchased from The Jackson Laboratory (Bar Harbor, ME, USA), MUC1.Tg mice obtained from 
Dr. S. Gendler (Mayo Clinic, Scottsdale, AZ, USA), and VFT TCR-transgenic mice (158) were 
housed in a AALAC approved SPF environment at the Univeristy of Pittsburgh.  All breeding 
and experimental procedures were approved by and performed in accordance with the University 
of Pittsburgh DLAR and IACUC guidelines. 
2.2.2 Production of Dendritic cells derived from bone marrow (BMDC) 
Dendritic cells derived from bone marrow were generated as described previously(159). Bone 
marrow cells were harvested from the tibia and femur of WT mice, the RBC lysed, and plated at 
a density of 1.5X106 cells/ml in AIM-V media (Invitrogen) containing sodium pyruvate, 2-
mercaptoethanol, non-essential amino acids, and supplemented with 20ng/ml of granulocyte 
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macrophage colony stimulating factor (GM-CSF; Miltenyi Biotec).  BMDC were harvested on 
day 6 of culture and loaded with either MUC1 or OVA peptide overnight in the presence of 
either 50µg/ml poly:ICLC (Hiltonol®) (Oncovir, Inc) or LPS. The 100-mer MUC1 peptide 
represents 5 repeats of a 20 amino acid sequence HGVTSAPDTRPAPGSTAPPA found in the 
VNTR region(160). 
2.2.3 In vitro T cell stimulation assay 
CD4 T cells from VFT TCR transgenic or OT-II TCR transgenic mice were isolated via 
magnetic bead separation and plated either alone or in conjunction with splenocytes (1:10) in a 6 
well plate and allowed to rest for 2 hours at 37°C.   A stimulant was added to the culture 
(cytokine, PMA/IONO, H2O2, DC (1:5)) and incubated for various periods of time at 37°C.  
Cells were fixed immediately with 1.6% paraformaldehyde final concentration (Electron 
Microscopy Services) for 10 minutes at room temperature.  Cells were then permeabilized in ice-
cold methanol for 30 minutes at 4°C and stored at -80°C until staining followed analysis by flow 
cytometry. 
2.2.4 Adoptive T cell transfer 
Splenocytes from VFT or OT-II transgenic mice were isolated and RBC lysed.   Magnetic bead 
isolation of CD4 T cells was performed via manufacture’s instructions (Miltenyi Biotec). Only 
OT-II TCR.Tg CD4 T cells were labeled with 2µmol/L carboxyfluorescein diacetate 
succinimidyl ester (CFSE; Invitrogen) prior to transfer, as VFT TCR.Tg mice are on the Thy1.1 
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congenic background for T cell identification.  5x106(per strain where co-transfer applicable) 
were injected via the lateral tail vein or the hind footpad 1-2 days pre vaccination. 
2.2.5 In vivo stimulation 
Mice were immunized with either ~3x106 MUC1 peptide pulsed DC, OVA peptide pulsed DC, 
MUC1 peptide admixed with poly:ICLC or LPS, or poly:ICLC or LPS alone by lateral tail vein 
injection or in the footpad.  At various timepoints, lymphoid organs (ether spleens or lymph 
nodes) were harvested and immediately fixed by processing into a single cell suspension in 1.6% 
paraformaldehyde(152, 153, 156, 161) at room temperature for 10 minutes. Cells are then 
permeabilized by the addition of ice-cold methanol for 30 minutes at 4°C.  Samples are stored 
long-term at -80°C. 
2.2.6 Detection of intracellular phosphorylation by flow cytometry 
A panel of intracellular candidates were selected based on signaling pathways associated 
with either Th1 signaling (the transcription factor Tbet as well as STAT1 (Y701) and STAT4 
(Y693) associated with Th1 costimulatory cytokines), Treg (the transcription factor FOXP3, 
STAT5 (Y694) associated with IL-2 signaling, as well as S6 (Y641) expression that inversely 
correlates with Treg induction), TCR activation (ZAP70 (Y319) and Lck (Y505)), cell survival 
and proliferation pathways (ERK1/2(T202/Y204), Akt(S473), p38MAPK(T180/Y182)) or 
signaling associated with differentiation of T helper cells(STAT3(Y705), STAT4(Y693), and 
STAT6(Y641)) (Table 1). Staining for the intracellular phospho-specific targets was done in 
conjunction with staining for surface markers as previously described(125).  Prior to Fc block for 
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20 minutes at room temperature, cells were pelleted and washed in staining buffer (PBS, 0.5% 
BSA, and 0.02% sodium azide) to remove residual methanol. Cells were then stained for 45 
minutes at room temperature in an antibody cocktail containing two intracellular markers as well 
as a mixture of surface antibodies including CD4 V500, B220 PeCy7, CD90.1 APC-eFluor 780 
(eBioscience), and an exclusion panel of biotin – streptavidin PE-Texas Red labeled antibodies 
(CD49b, TER119, CD11c, CD8a, F4/80, and CD11b) for better resolution of the populations of 
interest.   
Gating on Exclusion-B220-CD4+ T cells, we identified the transferred MUC1-specific 
VFT T cell response (Thy1.1+CFSE-) and/or the OVA-specific OT-II T cell response 
(CFSE+Thy1.1-).  Fold change was calculated by normalization of the Median Fluorescent 
Intensity (MFI) of the individual stimulated sample to the average MFI of the unstimulated 
samples.  In the case of co-transfer, fold change was calculated by normalization of the MFI of 
VFT T cells to the MFI of OT-II T cells in that same mouse. 
2.3 RESULTS 
2.3.1 Detection of phosphorylation after in vitro stimulation of established and primary cell 
lines 
The phospho-flow technique was established using human U937 and Jurkat cell lines; 
consequently it is an ideal starting point for validation of the technique.  Jurkat and U937 cells 
were subjected to PHA stimulation in order to establish the standard levels of signaling exhibited 
in our hands (Figure 2-1).  Phospho-flow was carried out as instructed in the ‘Basic Protocol 1’ 
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found in Current Protocols in Immunology, the original foundation on which all further 
optimization was built(161, 162).  Phosphorylation was induced as expected. Before proceeding 
with the confirmation of cytokine induced modification of molecules, we examined if there was 
any background signal, which would result from culture medium or the serum in the media in 
which cells were allowed to equilibrate.  If cells are being basally stimulated by serum or media 
components, low levels of detectable phosphorylation in the control cells could decrease the 
signal to background ratio.  However, if cells are in a stressed state that may also cause baseline 
phosphorylation to be higher, again decreasing the detected fold change.  Allowing cells to 
recover in media rather than PBS increased the fold change in phosphorylation detected (Figure 
2-2a), and the presence of serum did not appear to have an effect on the intensity of 
phosphorylation detected (Figure 2-2b). 
 
Figure 2-1.  Induction of signaling in Jurkat and U937 
Jurkat and U937 cell lines were stimulated with PHA for 15 minutes to detect ZAP70 (Y319), 38/MAPK 
(T180/Y182), ERK1/2 (T202/Y204), and Lck (Y505) phosphorylation events.  Cells were fixed in 1.6% PFA for 
10 minutes, permeabilized with MeOH, stained with antibody cocktail, and analyzed by flow cytometry.  
Increases in phosphorylation recapitulated similar increases in fold changes over unstimulated cells as reported 
in literature. 
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Figure 2-2. Effect of media on the strength of signal to noise ratio. 
 
We next confirmed that detection of phosphorylation of specific target molecules would 
be induced upon upstream receptor stimulation. Homogenous cells were given a bolus of 
stimulus inducing rapid phosphorylation of the target until the signal peaked and began to 
deteriorate.  Stimulation of Jurkat cells with IFNγ, IL-4, or PMA/IONO demonstrates a robust 
increase in the phosphorylation of STAT1, STAT4, or ERK1/2 and p38/MAPK respectively 
(Figure 2-3a).  As expected, a robust increase in phosphorylation was also induced after 
stimulation of WT splenocytes with IFNγ, IL-4, IL-6, PMA/IONO, GMCSF, or H2O2 compared 
(a) Jurkat T cells that recover to resting state in medium, rather than PBS, displayed greater increases in the 
detection of phosphorylation signaling compared to unstimulated controls. Cells were stimulated with 
PMA/IONO [500ng/ml,1μM], IFNγ [1000U/ml], IL-6 [10ng/ml], IL-4 [10ng/ml]for 15 minutes to detect 
phosphorylation of ERK1/2 (T202/Y204), STAT1 (Y701), STAT3 (Y705), and STAT6 (Y641) respectively.   
Cells were stimulated with 3% H2O2 for 10 minutes to detect ZAP70 (Y319) and Akt (S473) phosphorylation.  
Cells were fixed in 1.6% PFA for 10 minutes, permeabilized with MeOH, stained with antibody cocktail, and 
analyzed by flow cytometry. (b) Variations in the percentage of serum in the media or changing the media to 
fresh media upon stimulation had no significant affect on phosphorylation levels. Jurkat cells were stimulated 
with IL-4 [10ng/ml] for 15 minutes either in the presence of 10% FBS, serum free media, or no addition of 
media with the stimulus.  Cells were fixed in 1.6% PFA for 10 minutes, permeabilized with MeOH, stained with 
antibody cocktail, and analyzed by flow cytometry. 
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to unstimulated cells (Figure 2-3b,c) establishing that the protocol and antibodies were effective 
in primary mouse cells.   
 
 
Figure 2-3. Intracellular phosphorylation of targeted molecules in human cell lines and mouse primary cell 
lines post stimulation 
Jurkat T cells (a) and primary mouse splenocytes (b,c) were incubated with indicated stimuli for 15 minutes at 
37°C, with the exception of cells examined for ZAP70 (Y319) and Lck (Y505) that were stimulated for 5 
minutes.  Cells were fixed in 1.6% PFA for 10 minutes, permeabilized with MeOH, stained with antibody 
cocktail, and analyzed by flow cytometry. 
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Validation of the sensitivity of the phospho-flow technique was shown by dose dependent 
detection of phosphorylation (Figure 2-4a).  In addition, it was determined that the use of BD 
buffer systems did not increase the sensitivity of the assay to detect phosphorylation as compared 
to PFA/MeOH protocols (Figure 2-4b).  We also validated that the technique was sensitive and 
stringent enough in our hands to detect the transient phosphorylation in cells after stimulation 
within a 40-minute time course.  The phosphorylation of ZAP70 in Jurkat T cells was seen to 
peak at five minutes post stimulation with a Jurkat-specific anti-TCR antibody then progressively 
decrease until baseline (Figure 2-4c). These results were confirmed by western (data not shown).    
 
Figure 2-4.  Sensitivity of detection of intracellular phosphorylation levels 
(a) Splenocytes from mice were incubated for 15 minutes with either IFNγ and IL-6 or either alone at either 
[100ng/ml] or [10ng/ml]. Cells were fixed in 1.6% PFA for 10 minutes, permeabilized with MeOH, stained with 
antibody cocktail, and analyzed for STAT1 (Y701) phosphorylation by flow cytometry. (b) Mouse splenocytes 
were treated with H2O2 for 10 minutes.  Half the cells were fixed in 1.6% PFA for 10 minutes and permeabilized 
with MeOH, while the other half were fixed and permeabilized in the BD Buffer system per manufacturer’s 
instructions.  All cells were then stained with antibody cocktail, and analyzed for phosphorylation of ZAP70 
(Y319) by  
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The antigen-specific stimulation of cells in vivo results in activation of far fewer cells 
than does polyclonal activation of cells in vitro. Thus, in order to analyze a significant population 
of antigen-specific cells the overall number of cells analyzed would need to greatly increase.  To 
determine if staining parameters are within the thresholds of detection, we looked at a 1:5 and 
1:10 dilutions of antibody based on the recommended concentration as well as varying the 
number of cells in the staining volume.  Lower concentrations of antibody did not cause a 
significant decrease in the intensity of staining (Figure 2-5a).  However, an increase in the 
concentration of cells revealed a threshold at the level of 10 million cells/100μl that resulted in a 
definitive decrease in intensity of staining (Figure 2-5b).  Therefore, all future staining was 
performed at cellular concentration of no greater than 50 million cells per milliliter. 
 
Figure 2-5.  Determination of signal intensity of intracellular phosphorylation post stimulation 
(a) Jurkat and U937 cells were stimulated with 3% H2O2 for 10 minutes and stained at the same cellular 
concentration but with two titrations of the anti-phospho antibodies. Cells were fixed in 1.6% PFA for 10 minutes, 
permeabilized with MeOH, stained with antibody cocktail, and analyzed for STAT1 (Y701) phosphorylation by 
flow cytometry. (b) Jurkat cells were stimulated with IL-6 [10ng/ml] for 15 minutes before fixation.  Cells were 
stained at three different cellular concentrations and a 1:10 dilution of the recommended antibody concentration. 
flow cytometry.  The BD Buffer system did not increase the sensitivity of detection. (c) Jurkat cells were 
incubated with a Jurkat specific anti-TCR antibody.  Cells were fixed at various timepoints with 1.6% PFA, 
permeabilized, and analyzed as stated previously. 
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2.3.2 Intracellular phosphorylation signatures of CD4 T cells after in vivo stimulation with 
DC loaded with antigen  
Timepoints of one and six hours were chosen to assess early signaling in a polyclonal response 
after DC immunization.  An alloantigen was chosen since it would be expected to elicit a robust 
endogenous polyclonal response in comparison to the much more restricted response elicited by 
a foreign protein or peptide antigen.  Immunization of B6 WT mice with DC loaded with 
BALB/c lysate produced detectable increases of phosphorylation over B6 WT mice immunized 
with unloaded DC (Figure 2-6a,b).  Of note, the phosphorylation patterns were variable between 
mice.  However, based on data obtained with an admittedly low number of mice (n=2) in the 
preliminary study, we proceeded to determine the signaling fingerprint of CD4 T cells 
responding to foreign antigen. 
 
Figure 2-6.  Detection of intracellular signaling molecules in wildtype mice after allo immunization 
Spleens were harvested from C57BL/6 mice one and six hours after DC vaccination of BALB/c lysate or control 
vaccination and immediately fixed in 1.6% PFA for 15 minutes and then MeOH permeabilized.  Phosphorylation  
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The variation in signaling patterns between mice was more evident in attempts to 
determine the signaling signatures in MUC1-specific CD4 T cells responding to immunization 
with DC loaded with MUC1 peptide in MUC1.Tg mice (n=3) and WT mice (n=3) at various 
early timepoints (1, 6, 12, and 24 hours). Although variation from mouse to mouse within groups 
was sizeable, and the baseline phosphorylation levels of unstimulated mice appeared high 
creating a large signal to noise ratio; several differences in signaling between MUC1.Tg and WT 
mice were observed.  MUC1-specific CD4 T cells exhibited greater expression of 
phosphorylated STAT1 and Tbet at 24 hours post vaccination as compared to MUC1-specific T 
cells in the wildtype mice, as well as an increased phosphorylation of STAT4 at 1 hour (Figure 
2-7a).  The observed initial increase in activation of Th1 associated molecules at 24 hours 
suggests differentiation into the Th1 lineage cell fate in MUC1.Tg mice.  In addition to 
increasing phosphorylation of Th1 associated pathways, MUC1-specific T cells also exhibited an 
increase in ZAP70 phosphorylation and a decreased phosphorylation of Lck tyrosine 505 in 
MUC1.Tg mice (Figure 2-7b). When this tyrosine is phosphorylated it promotes the formation 
of a closed conformation, which prevents Lck activation.  Initial activation of signaling 
molecules downstream of the TCR is greater in MUC1-specific CD4 T cells in MUC1.Tg mice 
versus WT. However MUC1.Tg mice appear to have a dichotomous response, T cells from 
MUC1.Tg mice display an impaired ability to increase phosphorylation of early transient 
activation markers FOXP3 and STAT5 respectively in MUC1.Tg as compared to WT (Figure 
2-7c).  In addition, MUC1-specific T cells in WT but not MUC1.Tg display an impaired ability 
of signaling molecules was detected by flow cytometry. (a) Representative histogram of detection of intracellular 
phosphorylation of S6 (Y641). (b) Heatmap depicting fold changes in intracellular phosphorylation in two B6 
WT mice. 
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to increase phosphorylation of S6, which is inversely proportional to later Treg 
development(163). More endogenous regulatory cells are observed post vaccination in MUC1.Tg 
mice, and MUC1-specific CD4 T cells do not decrease regulatory signaling within the first 24 
hours (Figure 2-7c).  In addition, phosphorylation of ERK1/2 decreased in MUC1-specific cells 
in WT but not MUC1.Tg mice at one hour while phosphorylation levels of 38/MAPK decreased 
in MUC1-specific cells in MUC1.Tg but not WT at six hours post vaccination. Activation of Akt 
was equivalent over the first 24 hours in MUC1.Tg and WT mice.  Taken together these data 
suggest less proliferation of MUC1-specific T cells in MUC1.Tg compared to WT mice (Figure 
2-7d).   While initial experiments appeared to indicate that differences in the quality of early 
signaling in response to MUC1 immunization in MUC1.Tg compared to WT mice, statistical 
significance was not reached perhaps due to the large variability within each group.  
The number of cells that exhibited phosphorylation of the targeted molecules was then 
examined to see if a difference existed in the quantity of the response, i.e. the number of cells 
responding (Figure 2-8).  Fewer VFT T cells activated STAT1 and Lck but more activated Tbet 
in MUC1.Tg mice than in WT mice.  However, again no statistically significant differences were 
seen in the number of cells with increased phosphorylation of these targets between the two 
groups.  We thought that perhaps the variability could be reduced and a robust accurate T cell 
signature produced if we could corroborate the results with in vitro findings in the same system. 
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Figure 2-7.  In vivo T cell ‘phospho-fingerprint’ in response to MUC1 pulsed DC vaccination 
MUC1-specific T cells from the VFT TCR Tg mouse were adoptively transferred into MUC1.Tg and WT mice 
one day prior to DC vaccination with MUC1 100mer or unloaded DCs (n=3 mice/group).  Spleens were fixed 
and methanol permeabilized immediately upon harvest 1, 6, 12, and 24 hours post vaccination.  Phosphorylation 
of classical Th1 signaling proteins (a), proteins downstream of TCR activation (b), molecules associated with 
regulation (c), and proteins involved in cell cycle, survival, and signal transduction downstream of inflammatory 
mediators (d) were detected by flow cytometry. 
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Figure 2-8.  Percentages of cells expressing phosphorylated candidates 
 
 
VFT T cells were adoptively transferred into MUC1.Tg and WT mice one day prior to i.v. injection of 
poly:ICLC MUC1 pulsed DC or unloaded DCs (n=3 mice/group).  Spleens were harvested 1, 6, 12, and 24 hours 
post vaccination, and the percentage of T cells exhibiting phosphorylation of the indicated targets above that of 
unstimulated T cells was analyzed. 
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2.3.3 Detection of intracellular signaling pathways in MUC1-specific CD4 T cells  in vitro 
stimulation with DC 
Variability observed upon ex vivo examination of signaling events that occurred in vivo could be 
caused by a multitude of factors: the time it takes the antigen to reach the lymph node, the time 
elapsed between initial APC:T cell interaction and fixation of the cells, and/or dilution of the 
signal resulting from only a few cells in the MUC1-specific population responding to antigen at 
the specific timepoint.  To address these facets of the response, we examined the phosphorylation 
status of the targeted molecules in VFT CD4 T cells after in vitro stimulation with either 
unloaded DC or DC pulsed with MUC1 100mer peptide.  Since VFT CD4 T cells demonstrated 
normal proliferative and functional properties in WT mice, compared to MUC1.Tg, the 
deficiency in response is not inherent to the VFT T cell, but rather the microenvironment is the 
likely reason for the differences in functional and proliferative responses.  To accurately model 
the in vivo signaling response in vitro, we co-cultured the VFT CD4 T cells with either 
MUC1.Tg splenocytes or WT splenocytes. After allowing the cells to rest for two hours at 37°C 
to reach equilibrium, either MUC1 pulsed DC or unloaded DC were added to stimulate the 
culture.  Cells were harvested at 15min, 30 min, 45 min, 1 hour, 6 hour, and 24 hour after 
stimulation. Standard fixation, permeabilization, and staining were performed followed by 
analysis.  Unfortunately, the groups stimulated with MUC1 pulsed DC demonstrated no 
significant increase in phosphorylation over the baseline signaling seen by stimulation with DC 
alone in either MUC1.Tg or WT mice (Figure 2-9). 
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Figure 2-9.  Intracellular signaling detected at various timepoints after in vitro stimulation with DC pulsed 
with MUC1 peptide 
MACs purified CD4+ T cells from VFT TCR transgenic mice were co-cultured with either MUC1.Tg or WT 
splenocytes at a 1:10 ratio and allowed to rest for 2 hours at 37°C.  Cells were stimulated with either poly:ICLC 
matured MUC1 pulsed DC or unloaded DC at a 1:5 ratio.  At various timepoints, cells were fixed in 1.6% PFA, 
permeabilized, stained with antibody cocktail, and analyzed by flow cytometry. 
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Since the levels of phosphorylation were high in both groups stimulated with DC pulsed 
with antigen as well as the DC matured without antigen, it is possible that in vitro-matured DC 
were highly immunogenic themselves and caused activation of the non-cognate antigen specific 
cells.  Therefore, we examined if the in vitro stimulation of T cells with in vivo-generated DC 
harvested from spleens of vaccinated mice could recapitulate intracellular signaling differences 
detected ex vivo after in vivo stimulation of T cells, while increasing the signal strength.  Neither 
the use of bulk splenocytes (Figure 2-10a) nor MACS isolated CD11c+ DC (Figure 2-10b) 
harvested from mice immunized with MUC1 100mer admixed LPS in comparison to LPS alone 
enhanced the strength of the antigen-specific phosphorylation signal-to-noise ratio.   
 
Figure 2-10.  In vitro stimulation of T cells with DC matured in vivo 
At this point, in vitro DC stimulation of MUC1-specific T cells was not yielding the 
robust signaling we had anticipated would be present.  The differences we had initially seen in T 
cell activation after DC immunization in vivo, appeared dependent on the microenvironment or 
events that transpire in vivo that were not being successfully replicated in vitro.  Therefore, we 
examined if signaling events in CD4 T cells activated in vivo by DC immunization could be 
enhanced and sustained upon re-stimulation ex vivo. However, we found that MUC1-specific 
MUC1.Tg and WT mice were immunized i.v. with MUC1 100mer admixed LPS or LPS alone.  Spleens were 
harvested after 48 hours, and either (a) bulk splenocytes or (b) MACS isolated CD11c+ DC were co cultured 
with VFT CD4 T cells for various timepoints.     
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CD4 T cells exhibit some differences in phosphorylation after PHA re-stimulation compared to 
in vivo signaling at three hours post vaccination and is not consistently a more robust signal 
(Figure 2-11). 
 
Figure 2-11.  Differences in CD4 T cell signaling after re-stimulation 
2.3.4 Neither antigen nor route of administration impacted the detection of signaling, but co-
transfer of cells recognizing a non-cognate antigen as a baseline improved data quality 
Although MUC1 is a potent TAA, there are foreign antigen systems that have 
demonstrated a much more robust response, such as OT-II TCR transgenic CD4 T cells that 
recognize their cognate antigen ovalbumin (OVA).  We therefore tested whether the changes 
detected in a more robust TCR transgenic system would be more pronounced.  However, 
intracellular phosphorylation detected after both in vitro (Figure 2-12a) and in vivo (Figure 
VFT T cells were adoptively transferred into MUC1.Tg and WT mice one day prior to immunization with 
poly:ICLC matured DC pulsed with MUC1 100mer or DC alone. Three hours post immunization, spleens from 
WT and MUC1.Tg mice were harvested.  One half of the splenocytes from each mouse were fixed in 1.6% PFA 
and MeOH permeabilized for staining, and the other half were allowed to equilibrate to baseline for two hours at 
37°C.  Cells were restimulated with PHA for fifteen minutes, fixed, and permeabilized.  Cells were stained and 
analyzed. 
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2-12b) stimulation of OVA-specific CD4 T cells were similar in intensity as the signal strength 
in MUC1-specific T cells. 
 
Figure 2-12.  Intracellular signaling in OVA-specific cells in response to stimulation 
 
Decreasing the variability detected in responses, as well as accounting for any other 
intrinsic factors that may be contributing to such variability in individual mice could reduce the 
background noise, thereby increasing the window of detection.  The co-transfer of TCR T cells 
whose cognate antigen is not endogenous to the system, i.e. OVA-specific T cells, could permit 
better control for inter-mouse variation by creating a baseline of phosphorylation within the same 
mouse in which the MUC1-specific response is being measured. Obviously, useful results from 
such an approach are contingent on there being a low to no bystander effect on T cell activation.  
Indeed, normalization of MUC1-specific CD4 T cells to co-transferred OT-II CD4 T cells post 
immunization with MUC1 pulsed DC (Figure 2-13b) yields a more robust phosphorylation 
signature then normalization to unloaded DC immunization in separate mice (Figure 2-13a).  
(a) Phosphorylation of Akt in OT-II and VFT CD4 T cells in response to in vitro stimulation for fifteen minutes 
with H2O2 or DC pulsed with cognate antigen were compared by phospho-flow analysis.  (b) MACS purified 
OT-II CD4+ T cells were adoptively transferred to B6 WT mice one day prior to immunization with poly:ICLC 
matured DC pulsed with OVA peptide.  Spleens were harvested one and six hours post immunization.  Cells 
were fixed, permeabilized and phosphorylation was analyzed by flow cytometry. 
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Figure 2-13.  Improved detection of inducible signaling when non-cognate antigen-specific T cells are co-
transferred to determine basal levels of phosphorylation 
Either MACS isolated VFT CD4+ T cells (a) or a combination of VFT and CFSE-labeled OT-II T cells (b) were 
transferred into MUC1.Tg and WT mice two days prior to immunization. Spleens were harvested three hours post 
immunization with poly:ICLC matured DC pulsed with MUC1 100mer peptide or unloaded DC.  Cells were fixed, 
permeabilized, and phosphorylation assessed by flow cytometry. 
 
Another factor that may affect the quality of signaling or detection thereof is the route of 
administration of the antigen.  Antigen delivered intravenously will travel through the lung to the 
spleen, while antigen delivered to the footpad, a combination of intradermal and subcutaneous 
injection goes directly to the draining popliteal lymph node.  However, neither the concentration 
of the T ells present in the lymph node nor the route the DC travel (a shorter more direct path 
bypassing the lung) had an impact on the intensity of the phosphorylation signal detected 
(Figure 2-14).  
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Figure 2-14.  Strength of the signaling events detected were similar across different routes of administration 
and lymphoid organs.  
 
2.4 DISCUSSION 
There are several phospho-flow protocols in the literature that vary slightly in incubation times, 
incubation temperatures, and the concentration of fixative used.  Many permutations of small 
technical details such as antibody concentrations, the duration of incubation with antibodies,  
fixative concentration, methanol permeabilization time, removal of fixative prior to 
permeabilization, procedural temperatures, as well as rehydration of the sample prior to staining 
were all examined.  Many factors had no effect, but any parameter permutations that did increase 
the signal to noise ratio such as rehydration and the removal of fixative prior to permeabilization 
were reflected in the modified phospho-flow protocol used for all troubleshooting to boost 
signaling detection presented here. 
Equivalent numbers of MACS purified CD4+ VFT and OT-II T cells were adoptively co-transferred to 
MUC1.Tg mice.  One day later mice received either an i.v. or footpad injection of poly:ICLC matured DC 
pulsed with MUC1 100mer peptide.  Three hours post injection spleens (i.v.) or popliteal lymph nodes (footpad), 
respectively, were harvested. Cells were, fixed, permeabilized, and phosphorylation analyzed by flow cytometry. 
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The robust signaling seen after cells were stimulated in vitro with cytokines, prompted us 
to try to optimize the detection of antigen receptor signaling and boost the phosphorylation 
detected.  In vitro experiments, including co-culture with MUC1.Tg or WT splenocytes and 
stimulation with DC activated in vivo, demonstrated no differences in signaling in CD4 T cells 
upon external stimulation indicating the importance of cues from the microenvironment which 
we were not able to recapitulate in vitro.  Therefore, we tried to optimize signaling detection by 
the development of an ex vivo re-stimulation assay that would capture more robust differences in 
phosphorylation.  Ex vivo experiments demonstrated that the ex vivo signaling fingerprint did 
not always reflect the same phosphorylation patterns before and after re-stimulation.  
Furthermore, re-stimulation did not consistently result in the detection of greater levels of 
phosphorylation.  In addition, the use of a different adjuvant or antigen system did not result in 
greater detection of phosphorylation.  However, co-transfer of TCR transgenic T cells that 
recognized a cognate antigen in conjunction with non-cognate TCR transgenic T cells as a 
baseline of phosphorylation, resulted in a greater window of phosphorylation detection  and 
reduced the variability of the calculated fold change between mice. This optimization in 
experimental design allows for the use of the phospho-technique to assess phospho-signatures 
after in vivo stimulation of cells.  These phospho-signatures can be predictive of the efficacy of 
vaccines in preclinical models, correlated to experimental outcomes, and eventually used as a 
biomarker of immunogenicity and disease outcome in clinical trials. 
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3.0  EARLY IN VIVO SIGNALING PROFILES IN MUC1-SPECIFIC CD4 T CELLS 
RESPONDING TO TWO DIFFERENT MUC1 VACCINES IN TWO DIFFERENT 
MICROENVIRONMENTS 
Chapter 3 has been adapted from Reichenbach, D.K., and O.J. Finn. Early invivo signaling 
profiles in MUC1-specific CD4T cells responding to two different MUC1 vaccines in two 
different microenvironments. 2013. OncoImmunology. 2(3); with permission from Landes 
Biosciences.  Copyright permission is kept on file with Dawn K. Reichenbach. 
3.1 INTRODUCTION 
Cancer immunotherapy is gaining recognition not only as an important addition to standard 
radiation and chemotherapeutic approaches but also as an effective monotherapy(38). Cancer 
vaccines are one form of immunotherapy that could benefit advanced cancer patients by boosting 
their anti-cancer immune response, as well as by aiding in cancer prevention for individuals who 
are at high risk for cancer.  Over the last three decades, there have been great advances in the 
characterization of immune responses in cancer patients and types of immunity required to 
control various tumors.  This research has also identified numerous tumor antigens recognized by 
tumor specific T cells that have been used to develop and test cancer vaccines.  Preclinical 
animal models, in particular genetically engineered mice, have been very useful in testing 
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immunogenicity of cancer vaccines and anti-tumor efficacy. These studies have shown that to be 
effective a vaccine needs to elicit a vigorous effector T cell response, including a robust memory 
response.   The ability of a vaccine to do this depends on the choice of tumor antigen(s), choice 
of adjuvant(s), and the patient’s immune competence. The majority of well-characterized tumor 
antigens (66) are tumor-associated antigens that are closely related to self-antigens and may be 
subjected to various degrees of self-tolerance. The choices of adjuvant and antigen delivery 
systems (e.g. loaded on DC, in viral vectors, conjugated to antibodies targeting DC) are 
important determinant of both the strength and the type of immune response elicited. These 
variables, in addition to others, determine the efficacy of a single vaccine across patients.  Cancer 
vaccine efficacy can be evaluated by two outcomes: 1) immunogenicity, measured as production 
of new antibodies and T cells several weeks after vaccination, and 2) tumor control, measured 
weeks after vaccination in mouse models or months and years after vaccination in patients.  In 
the case of vaccines for cancer prevention, evaluation of efficacy would be even more delayed. 
According to many animal models and some clinical trials, these two outcomes are tightly 
correlated – the more robust the antibody and T cell responses induced by the vaccine, the better 
tumor control in the future. The goal of the work we report here was to evaluate in vivo a 
technique that has been used successfully to measure activation of T cells in vitro, in order to 
determine if an early T cell activation signature can be obtained in primary T cells that might be 
developed as a predictive biomarker of a vaccine efficacy.  
CD4 T cells play a central role in the generation and quality of CD8 cytotoxic T cells (CTL), 
antibodies, and the induction of memory.  In addition, they participate in the activation and 
recruitment of innate effector cells to the tumor site(164-166). Therefore, the ability of a vaccine 
to activate CD4 T cells could be an important biomarker of its efficacy.  
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Mucin 1 (MUC1) is an O-linked glycosylated transmembrane protein normally expressed on 
the apical surface of ductal epithelial cells, but it is also found aberrantly expressed in a broad 
spectrum of adenocarcinomas. Upon malignant transformation of cells, MUC1 loses polarity and 
becomes overexpressed and hypoglycosylated revealing a region of tandem repeats of a 20 
amino acids sequence rendering itself immunogenic. Low T cell and antibody responses to 
MUC1 have been seen in patients with adenocarcinomas prompting development of vaccines to 
boost that response. 
Previously, we have shown that a MUC1 peptide loaded DC (DC-MUC1) vaccine elicits 
more effective anti-tumor responses than a MUC1 peptide in conjunction with poly:ICLC 
(MUC1-poly:ICLC) vaccine(121).  Furthermore we showed that MUC1-specific T cells 
proliferate less and produce less IFN-γ in response to both vaccines in MUC1.Tg compared to 
WT mice(158, 160).  These findings yielded a relevant model system for investigating potential 
early biomarkers that are associated with these different outcomes.  
Development of flow cytometry based assays, a technique known as phospho-flow, has 
allowed for complex signaling networks to be identified within single cells(125-128). Phospho-
flow has already been used to investigate STAT activation in T cells from late stage cancer 
patients(132), shifts in signaling potentials in leukocytes of acute myeloid leukemia 
patients(130), deficiencies of STAT signaling in monocytes of HIV infected individuals(131), 
and even attempts to predict clinical responsiveness to therapies for Rheumatoid Arthritis(133). 
Here we use this technique for the first time on tumor antigen specific primary T cells to evaluate 
differences in the quality (what pathways are activated and their kinetics) and the quantity 
(strength of phosphorylation) of immune responses elicited by two different MUC1 vaccines in 
two different mouse strains. We hypothesized that differences we previously reported in the 
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immunogenicity and efficacy of these vaccines in different hosts, measured weeks and months 
after vaccination, might be predicted by the state of CD4 T cell activation immediately after 
vaccination.  We show that this is indeed the case and that the phosphorylation profile of MUC1-
specific TCR transgenic CD4 T cells at 3, 6, 12 and 24 hours after vaccination is different in 
response to soluble peptide plus adjuvant versus peptide loaded on DC.  
We propose that other vaccines can be similarly compared to identify the most immunogenic 
ones, with the most robust T cell activation signature to select best candidates for further 
development. 
3.2 METHODS 
3.2.1 Mice 
C57BL/6 (WT) and C57BL/6-Tg (TcraTcrb)42SCbn/J (OT-II TCR-transgenic) mice were 
purchased from The Jackson Laboratory (Bar Harbor, ME, USA), MUC1.Tg mice were 
originally obtained from Dr. S. Gendler (Mayo Clinic, Scottsdale, AZ, USA), and VFT TCR-
transgenic mice were generated at the University of Pittsburgh transgenic mouse facility as 
previously described(158). All mice were housed in a specific pathogen free environment.  All 
breeding and experimental procedures were approved by and performed in accordance with the 
guidelines of the Institutional Animal Care and Use Committee of the University of Pittsburgh.  
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3.2.2 Generation of Bone Marrow Dendritic Cells (BMDC) 
BMDC were generated as previously described(159).  In brief, bone marrow cells were harvested 
from the tibia and femur of WT mice.  Following RBC lysis, BM cells were plated at 1.5X106 
cells/ml in AIM-V media (Invitrogen) containing sodium pyruvate, 2-mercaptoethanol, non-
essential amino acids, and supplemented with 20ng/ml of granulocyte macrophage colony 
stimulating factor (GM-CSF; Miltenyi Biotec).  On day 3 of culture, half the medium was 
replaced with fresh AIM-V and 20ng/ml of GMCSF.  On day 6 of culture, BMDC were 
harvested, counted, and loaded with MUC1 peptide overnight in the presence of 50µg/ml 
poly:ICLC (Hiltonol) (Oncovir, Inc).  The 100-mer MUC1 peptide represents 5 repeats of a 20 
amino acid sequence HGVTSAPDTRPAPGSTAPPA found in the VNTR region of Mucin 1.  Its 
synthesis and quality assurance was carried out at the University of Pittsburgh Genomics and 
Proteomics Core Laboratories(160). 
3.2.3 Adoptive T cell transfers 
Spleens were harvested from VFT and OT-II TCR transgenic mice, mechanically processed into 
single cell suspensions, and subjected to RBC lysis.  CD4 T cells were negatively isolated by 
magnetic bead separation per manufacturer’s instructions (Miltenyi Biotec). VFT TCR-Tg CD4 
T cells were distinguishable from endogenous cells via Thy1.1 congenic background, therefore 
only OT-II TCR-Tg CD4 T cells were labeled with 2µmol/L carboxyfluorescein diacetate 
succinimidyl ester (CFSE; Invitrogen) prior to transfer. Equivalent numbers of CD4 VFT and 
OT-II T cells (3x106 -5x106/strain) were injected via the lateral tail vein 1-2 days pre 
vaccination. 
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3.2.4 In vivo Stimulation 
For immunization, each mouse received either a DC-based vaccination of 3x106 MUC1 peptide 
loaded BMDC or a MUC1- poly:ICLC vaccination comprising of 100µg MUC1 peptide and 
50µg of poly:ICLC by lateral tail vein injection.  Splenocytes were harvested and processed for 
phospho-flow analysis as described previously(152, 153, 156, 161).  In brief, spleens were 
harvested at various timepoints post immunization and fixed immediately by processing into a 
single cell suspension in 1.6% paraformaldehyde (Electron Microscopy Services).  After fixation 
for 10 minutes at room temperature, cells were permeabilized with the addition of ice-cold 
methanol to a final concentration of 80%.  Samples were incubated for 30 minutes at 4°C before 
being stored at -80°C. 
3.2.5 Optimization of the phospho-flow technique for analysis of primary T cells 
Intracellular phospho-specific staining was done in conjunction with staining for surface markers 
as previously described. (125) Briefly, cells were washed twice in staining buffer (PBS, 0.5% 
BSA, and 0.02% sodium azide) before blocking with an anti-CD16/32 antibody for 20 minutes at 
room temperature.  Cells were stained for 45 minutes at room temperature with a mixture of 
surface antibodies including CD4 V500, B220 PeCy7, CD90.1 APC-eFluor 780 (eBioscience), 
and an exclusion panel of biotin – streptavidin PE-Texas Red labeled antibodies (CD49b, 
TER119, CD11c, CD8a, F4/80, and CD11b) for better resolution of the populations of interest.  
Two intracellular or phospho-specific antibodies (Tbet Alexa Fluor 647, Akt Alexa Fluor 647 
(pS473), ERK1/2 PE (pT202/pY204), Lck Alexa Fluor 647(pY505), p38 MAPK Alexa Fluor 
647 (pT180/pY182), Stat1 PE (pY701), Stat3 PE (pY705), Stat4 PE (pY693), Stat5 PE (pY694), 
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Stat6 Alexa Fluor 647 (pY641), S6 Alexa Fluor 647 (pS244), Zap70 PE (Y319)) were used per 
sample.  After staining, all samples were washed and resuspended in staining buffer.  All 
antibodies were products of BD Biosciences unless noted otherwise. 
All samples were run on the LSR Fortessa and analyzed with Flowjo software (Treestar).  
The transferred MUC1 stimulated VFT CD4 T cell population (exclusion-CD4+B220-
CD90.1+CFSE-) as well as the co-transferred control OT-II population that does not respond to 
MUC1 peptide (exclusion-CD4+B220-CD90.1-CFSE+) were identified.  Median Fluorescent 
Intensity (MFI) was calculated for each population within the sample and used to calculate fold 
change upon stimulation after normalization to the corresponding fluorescence minus one (FMO) 
control (fold change = absolute value ([MFI stimulated /MFI stimulated FMO]/ [MFI unstimulated /MFI 
unstimulated FMO])) 
3.3 RESULTS 
3.3.1 Kinetics of TCR signaling in MUC1.Tg and WT mice in response to two different 
MUC1 vaccines 
We adoptively transferred MUC1-specific VFT T cells and control OT-II T cells into WT or 
MUC1 transgenic mice and immunized the mice with either DCs loaded with MUC1 peptide 
(DC-MUC1) vaccine or MUC1 peptide admixed with the adjuvant poly:ICLC (MUC1-
poly:ICLC) vaccine. We collected splenic T cells from 3 mice per group at each time point. After 
vaccination with the DC-MUC1 vaccine, MUC1-specific T cells displayed high levels of Zap70 
phosphorylation at 3hours in MUC1.Tg mice that was transient and not present in WT mice. At 6 
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hours the levels of Zap70 phosphorylation in MUC1.Tg mice was still present but at a much 
lower level, closer to that seen in WT mice (Figure 3-1a).  The percentage of MUC1-specific T 
cells expressing phosphorylated Zap70 was low (∼2%) in both strains.  In contrast, 
phosphorylation of Lck, which results in stabilization of the inactive conformation, was low but 
measurable at all time points and present in a large percentage of T cells (Figure 3-1b). In the 
case of the MUC1-poly:ICLC vaccine, MUC1-specific T cells had equivalent levels of 
phosphorylated Zap70 at 3 hours in WT and MUC1.Tg mice and a higher number of activated T 
cells at early time points. As with the DC-MUC1 vaccine, Lck phosphorylation was measurable 
at 6 hours (Figure 3-1a) and in a larger number of T cells in both MUC1.Tg and WT mice 
(Figure 3-1b).  Similar activation through their TCR and similar signaling of MUC1-specific T 
cells in response to both types of vaccines and in both MUC1.Tg and WT mice suggests that it is 
not this first step that is responsible for the ultimate difference in the vaccine outcome. 
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Figure 3-1.  Signaling through the TCR 
  
(a) Levels of phosphorylated ZAP and Lck were examined at 3, 6, 12, and 24 hours post vaccination with either 
DC-MUC1 (n=6/strain/timepoint except 12 hour (n=3)) or MUC1-poly:ICLC (n=6/strain/timepoint except 6 
hour (n=5)) in MUC1.Tg or WT mice.  The levels of phosphorylation in MUC1-specific T cells responding to 
DC-MUC1 vaccine was significantly different then seen in response to MUC1-poly:ICLC vaccine at (*p<0.05) 
12 hours by unpaired t-test.  (b) The corresponding number of THY1.1+ cells expressing the phosphorylated 
targets at each timepoint in response to vaccination was determined. The percent of cells responding to DC-
MUC1 vaccine was significantly different by unpaired t-test  (†††p<0.001) at 12 hours in comparison to 
responses to MUC1-poly:ICLC vaccine. 
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3.3.2 Activation of cell cycle and survival pathways post MUC1 vaccination in WT and 
MUC1.Tg mice 
Phosphorylation of ERK1/2 has been shown to be critical for T cell activation and proliferation 
in response to alloantigen in vivo(167) and was of interest for MUC1-specific responses.  We 
investigated MUC1-specific T cells responding to the two MUC1 vaccines in WT or MUC1.Tg 
mice for differences in phosphorylation of ERK1/2 downstream of TCR signaling in the Ras/Raf 
pathway and in two other tyrosine kinases, 38/MAPK and Akt, involved in cell survival and 
proliferation pathways.  Both Akt and 38/MAPK have also been shown to have roles in T cell 
differentiation and function(168, 169), and their activation is dependent on upstream co-
stimulatory signaling(170, 171).  
We found differences in the kinetics of ERK1/2 phosphorylation in MUC1.Tg compared 
to WT mice after DC-MUC1 vaccine.  At six hours, in MUC1.Tg mice we saw a small 
percentage of MUC1-specfic T cells experiencing a peak in ERK1/2 phosphorylation that 
quickly decreased by 12 hours after vaccination (Figure 3-2).  The signal peaked in WT mice at 
12 hours post vaccination.  Activation of 38/MAPK and Akt in response to DC-MUC1 was 
similar.  MUC1.Tg and WT mice exhibited low levels of 38/MAPK and Akt phosphorylation in 
a small percentage of MUC1-specific T cells. Phosphorylation of ERK1/2, 38/MAPK, and Akt in 
response to the MUC1-poly:ICLC vaccine was minimal but equivalent in MUC1.Tg and WT 
mice. Although activation of cell cycle and survival pathways in MUC1.Tg and WT mice 
following MUC1-poly:ICLC immunization trended the same in both the intensity and the 
percentage of cells, there was an initial increase in the subpopulation of MUC1-specific T cells 
expressing phosphorylated 38/MAPK and ERK1/2 not seen after DC-MUC1 immunization 
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(Figure 3-2b).  In summary, differences can be seen in ERK1/2 phosphorylation but not in 
38MAPK and Akt phosphorylation. 
 
Figure 3-2.  Activation of cell cycle and survival proteins 
(a) Key signaling molecules in the MAPK, Ras/Raf, and PI3K pathways (38/MAPK, ERK1/2, and Akt 
respectively) were analyzed for changes in phosphorylation in MUC1-specific T cells at 3, 6, 12, and 24 hours 
post immunization with either a DC-MUC1 (n=6/strain/timepoint except 12 hour (n=3)) or MUC1-poly:ICLC 
(n=6/strain/timepoint except 6 hour (n=5)) vaccines. The levels of phosphorylation in MUC1-specific T cells 
responding to DC-MUC1 vaccine was significantly different then seen in response to MUC1-poly:ICLC vaccine 
at (*p<0.05) 24 hours by unpaired t-test. (b) The percentage of MUC1-specific cells that elicited phosphorylation 
of p38/MAPK, ERK1/2, and Akt in response to the vaccines were determined.  The percent of cells responding 
to DC-MUC1 vaccine was significantly different by unpaired t-test  (pERK1/2; *p<0.05 and pAKT; ***p<0.001) 
at 3 hours in comparison to responses to MUC1-poly:ICLC vaccine.   
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3.3.3 Activation of Th1 associated signaling molecules in response to MUC1 vaccines in WT 
and MUC1.Tg mice 
We have previously published elicitation of MUC1-specific Th1 responses in both MUC1.Tg 
and WT mice following immunization with DC-MUC1 vaccine, but at the same time a decrease 
in IFNγ production by MUC1-specific cells in MUC1.Tg mice compared to WT mice. (158) 
Expecting this to be indicative of differences in the percentage of cells or the degree of 
phosphorylation of Th1 associated signaling molecules(160), we examined potential differences 
in phosphorylation of the Th1 associated signaling molecules downstream of IFNγ receptor 
signaling and IL-12 receptor signaling, STAT1 and STAT4 respectively, as well as expression of 
the transcription factor Tbet.  MUC1-specific T cells displayed phosphorylation of STAT1 to a 
much higher degree than STAT4 in both MUC1.Tg and WT mice at 3 and 6 hours post 
vaccination (Figure 3-3a).  Although activation of STATs occurs equivalently in both groups of 
mice after soluble vaccination, MUC1-specific T cells in MUC1.Tg mice exhibit greater 
activation of STAT1 in a higher percentage of the population at 3 hours after DC immunization 
than in WT mice (Figure 3-3).  In addition, from 6 through 24 hours post immunization there 
were consistently a greater percentage of MUC1-specfic T cells exhibiting STAT1 signaling in 
response to DC-MUC1 than MUC1-poly:ICLC vaccine (Figure 3-3b). Thus DC-MUC1 vaccine 
activates more robust Th1 signaling than MUC1-poly:ICLC vaccine in both strains of mice.  
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Figure 3-3.   Th1 associated signaling 
 
(a) Phosphorylation of signaling molecules downstream of cytokine receptors activated in a Th1 response, 
STAT1 and STAT4, as well as the expression transcription factor Tbet were examined at 3, 6, 12, and 24 hours 
post immunization with DC-MUC1 (n=6/strain/timepoint except 12 hour (n=3)) or MUC1-poly:ICLC 
(n=6/strain/timepoint except 6 hour (n=5)) vaccines.  (b) Percent of MUC1-specific T cells that exhibited 
phosphorylation of STAT1 or STAT4 or expressed Tbet above baseline was identified. The percent of cells 
responding to DC-MUC1 vaccine was significantly different by unpaired t-test  (***p<0.001) at 12 and 
(*p<0.05) 24 hours in comparison to responses to MUC1-poly:ICLC vaccine. 
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3.3.4 Th2 and Th17 associated signaling responses to MUC1 vaccines in MUC1-specific T 
cells 
We also examined the phosphorylation status of STAT6 and STAT3 in order to potentially be 
able to predict if a vaccine might be activating Th2 or Th17 cells that are not routinely measured 
in response to cancer vaccines.  STAT3 activation promotes Th17 differentiation(142, 172), 
while Th2 development requires STAT6 activation in addition to STAT3(173).  Following both 
DC-MUC1 and MUC1-poly:ICLC immunization, MUC1-specific T cells in MUC1.Tg and WT 
had equivalent percentages of cells exhibiting similar levels and kinetics of STAT6 and STAT3 
phosphorylation. In general, DC-MUC1 vaccine elicited robust STAT3 signaling in over 50% of 
MUC1-specific T cells in the first 24 hours (Figure 3-4b), with little to no increases in STAT6 
activation.  Furthermore, at 24 hours post immunization, there is greater phosphorylation of 
STAT3 in MUC1.Tg mice than in WT mice.  Conversely, MUC1-poly:ICLC immunization 
demonstrated greater levels of STAT6 activation than STAT3 at all timepoints (Figure 3-4a). 
Although there is initially a larger percentage of cells exhibiting STAT6 activation, as time 
progresses the population of MUC1-specific cells with activated STAT6 decreases to barely 
detectable levels while the population exhibiting STAT3 phosphorylation remains constant and 
high (Figure 3-4b).  
 68 
 
Figure 3-4.  Th2 and Th17 signaling 
 
(a) Phosphorylation of STAT3 and STAT6 signaling molecules in response to DC-MUC1 (n=6/strain/timepoint 
except 12 hour (n=3)) or MUC1-poly:ICLC (n=6/strain/timepoint except 6 hour (n=5)) vaccines in MUC1.Tg or 
WT mice was analyzed 3, 6, 12, and 24 hours post immunization. The levels of phosphorylation in MUC1-
specific T cells responding to DC-MUC1 vaccine was significantly different then seen in response to MUC1-
poly:ICLC vaccine at (***p<0.001) 12 and (**p<0.01) 24 hours by unpaired t-test.  (b) The percent of MUC1-
specific cells that phosphorylated STAT3 or STAT6 was determined.  The percent of cells responding with 
STAT3 phosphorylation to DC-MUC1 vaccine was significantly different by unpaired t-test  (*p<0.05) at 3, 6, 
and (***p<0.001) 12 hours post immunization in comparison to responses to MUC1-poly:ICLC vaccine.   
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3.3.5 Fewer MUC1-specific T cells show S6 activation after DC-MUC1 vaccine compared to 
MUC1-poly:ICLC vaccine 
We have previously published that regulatory T cells (Treg) affect MUC1-specific CD4 T cell 
responses in the MUC1.Tg mouse(160).  To assess if activation of Treg can be predicted for 
different vaccines in different hosts, we examined phosphorylation of S6 kinase downstream of 
the Akt/mTOR pathway that inversely correlates with subsequent Treg development(163) as well 
as STAT5 (the IL-2 receptor signaling molecule) and expression of the Treg transcription factor 
FOXP3. We found no differences in these molecules between T cells in vaccinated MUC1.Tg 
versus WT mice, with the exception of FOXP3 expression being higher in MUC1.Tg mice at the 
6-hour time point post DC-MUC1 vaccination (Figure 3-5a).  There was a difference however 
between the vaccines. MUC1-poly:ICLC vaccine elicited a much greater percentage of cells 
displaying S6 phosphorylation and significantly fewer cells exhibiting STAT5 phosphorylation 
then their counterparts receiving the DC-MUC1 vaccine (Figure 3-5b).    
 70 
 
Figure 3-5.  Pathways associated with signaling through T regulatory cells  
 
(a) Expression levels of FOXP3 and phosphorylation levels of STAT5 and S6 were examined at 3, 6, 12, and 24 
hours post DC-MUC1 (n=6/strain/timepoint except 12 hour (n=3)) or MUC1-poly:ICLC (n=6/strain/timepoint 
except 6 hour (n=5)) vaccination in MUC1.Tg and WT mice. The levels of phosphorylation in MUC1-specific T 
cells responding to DC-MUC1 vaccine was significantly different then seen in response to MUC1-poly:ICLC 
vaccine at (*p<0.05) 3 hours by unpaired t-test (b) The percent of MUC1-specific cells altering expression of 
FOXP3 or phosphorylation of STAT5 or S6 was determined. The percent of cells responding with STAT5 
phosphorylation to DC-MUC1 vaccine was significantly different by unpaired t-test  (***p<0.001) at 3, 6, and 
12 hours post immunization in comparison to responses to MUC1-poly:ICLC vaccine.  While the percentage of 
cells phosphorylating S6 in response to DC-MUC1 compared to MUC1-poly:ICLC differed at all timepoints 
((*p<0.05) 3, 6, and 24 hours; (***p<0.001) 12 hours). 
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3.3.6 Differences in signaling profiles hours post vaccination correlate with elicited T cell 
populations 
We analyzed cell surface activation markers on VFT T cells retrieved from WT or MUC1.Tg 
mice vaccinated with DC-MUC1 or MUC1-poly:ICLC vaccine whose signaling events we 
determined above. We found that a large percentage of these cells expressed CD25 regardless of 
their origin (MUC1.Tg vs WT mice) for the first 12 hours post DC-MUC1 immunization. By 24 
hours, however, the percentage of cells expressing CD25 had dropped significantly in WT mice.  
Conversely, CD69 expression was low for the first 6 hours post vaccination peaking at 12 hours 
with greater expression on cells from WT mice (Figure 3-6a). 
Since S6 inversely correlates with the development of Treg, we determined the 
percentage of FOXP3+CD4+ T cells in MUC1.Tg and WT mice post secondary boost with either 
DC-MUC1 or MUC1-poly:ICLC peptide vaccine.    Approximately 3% of CD4 T cells were 
FOXP3 positive in MUC1.Tg and WT mice vaccinated with MUC1-poly:ICLC. In contrast, DC-
MUC1 vaccine was more effective at stimulating Treg development, yielding twice as many 
FOXP3+ T cells (Figure 3-6b). 
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Figure 3-6.  Small differences in signaling yield differences in T cell outcome.    
 
Having a quantitative data set representing early activation of all the pathways that we 
chose because of their known importance in the development of an immune response to different 
vaccines in different hosts, allowed us to compile them together into one activation fingerprint.  
Figure 3-7 represents signaling signatures of MUC1-specific CD4 T cells responding to MUC1 
vaccines in MUC1.Tg mice, where MUC1 is a self-antigen, and in WT mice where it is a foreign 
antigen.  It is an example of the potential of this approach that will need to be validated further 
by comparing other vaccines and relating it to their known outcomes.  
(a) The expression of cell surface activation markers, CD25 and CD69, was examined on MUC1-specific T cells 
3, 6, 12, and 24 hours (n=3/strain/timepoint) post immunization with DC-MUC1 in MUC1.Tg and WT mice. * 
Indicates a p value = 0.012 by unpaired t-test. (b) MUC1.Tg and WT mice (n=3/strain) were vaccinated and 
boosted twice at four-week intervals. The endogenous CD4 T cell populations were examined at 24 hours post 
secondary boost for FOXP3 expression. 
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Figure 3-7.  Proposed model for a MUC1-specific CD4 T cells in vivo activation “fingerprint” 
 
The profile of the CD4 T cell population early post-vaccination composed of TCR, cell cycle and survival, and 
molecules associated with T helper and Treg activation in MUC1-specific T cells in response to DC-MUC1 and 
MUC1-poly:ICLC vaccines at 3, 6, 12, and 24 hours. 
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3.4 DISCUSSION 
The phospho-flow technique has proven dependable and reproducible in vitro(130).  There has 
been success in transferring this technique to in vivo models of stimulation in which a bolus of 
adjuvant(153) or a soluble antigen that can bind directly to the MHC cleft are administrated(156) 
but many hurdles still preclude its use for antigen-specific events. The time it takes for an 
antigen to be processed and the TCR:MHC synapse to form between DC and T cells within the 
spleen or lymph node can be variable between vaccines and between hosts. Furthermore, only a 
small number of cells within the population are being activated at a given moment with transient 
phosphorylation, therefore the signal is easily diluted, especially at very early time points.  
Nevertheless, we demonstrate that phosphorylation signatures of MUC1-specific T cells reacting 
to MUC1-poly:ICLC vaccination can be compared to DC-MUC1 vaccination and differences 
can be identified in the degree of signaling associated with Th1, Th2, Th17 and Treg responses, 
as well as activation of molecules that are key to cell survival and proliferation.    
In future studies it may be necessary to expand the panel of signaling molecules for a 
more precise T cell activation signature in response to vaccination.  Many of the signaling 
molecules we included have numerous downstream targets in different signaling pathways that 
they activate, and can also have multiple upstream modifiers.  This could hinder interpretation of 
the activation and differentiation of the T cell response and in turn affect prediction of vaccine 
efficacy.  For instance, an increase in phosphorylation of Akt could be indicative of cell growth, 
proliferation, or autophagy inhibition. A decrease in Akt activation suggests suppression of cell 
cycle progression but it may also be indicative of immune function, as it has been shown 
necessary for Treg suppressive function(174).  Signaling molecules within the cell may have 
various upstream activators; IL-6 receptor, IL-21 receptor, and CD40L all signal through 
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STAT3.  The role of STAT3 signaling has been well defined in the differentiation of T helper 
subsets, however it has also been shown to play a role in the maintenance and development in 
memory(175). In addition, the synthesis of IL-17 is dependent on downstream mediators of 
MAPK cascades that require the activation of 38/MAPK in CD4 T cells therefore placing 
38MAPK in a critical role in IL-17 production(176). Increases in phosphorylation in MAPK 
following immunization may be indicative of increased cell survival or perhaps a skewing 
towards a Th17 response.  These instances of crosstalk just demonstrate the importance of 
understanding the context and cell type in which signaling pathways are activated in order to 
extrapolate later effects on function or immune response. 
All caveats acknowledged, we were still able to demonstrate differences between the 
phosphorylation of signaling pathways, the intensity of phosphorylation of a protein, and the 
kinetics of activation dependent on whether it was a foreign (MUC1 in WT mice) or abnormal 
self-antigen (MUC1 in MUC1.Tg mice) being recognized by the immune response.  Modulation 
of these responses was possible by changing the design of the vaccine (peptide loaded DC or 
peptide in conjunction with adjuvant) creating unique signatures.  This suggests that with 
additional optimization and proper validation, just the signaling fingerprint obtainable within a 
few days post vaccination can serve as a biomarker of a vaccine efficacy.  Moreover, it can be a 
good way to assess if changes in design, modulation of its components, adjuvants and vehicles of 
delivery, produce a better vaccine. 
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4.0  DISCUSSION 
Evaluation of the effectiveness of a vaccine within an earlier time frame post administration is 
desirable to determine if the desired immune response is occurring.  The earlier the detection, the 
more quickly changes to therapeutic regimens can be implemented resulting in better 
establishment of the desired immune response.  To our knowledge, our work discussed here is 
the first to demonstrate that early T cell signaling signatures detected within 24 hours post 
vaccination were different dependent on vaccine design and host environment.  This suggests 
that T cell signaling signatures could be used to decipher the immune response to a vaccine in 
the context of the microenvironment, therefore serving as a biomarker of vaccine efficacy.  
Extrapolating from differences in the outcomes of tumor challenge that we already know exist 
after vaccination with the two MUC1 vaccines in the MUC1.Tg versus WT models, differences 
in these ‘fingerprints’ of activation may be correlated to differences in the outcome of disease.  
Furthermore, it can be an effective way to evaluate if changes in design, modulation of its 
components, adjuvants and vehicles of delivery, produce a better vaccine.  Because signaling is 
universal, the detection of a T cell activation ‘fingerprint’ representative of induction of 
protective immunity versus that of a tolerant response could be universally applied to any 
antigen, tumor model, or even disease.   
As previously discussed, the use of phospho-flow to examine differences in signaling in 
in vitro assays has been well characterized and reproducible.  The ability of this technique to 
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identify differences in the signaling potential of lymphocytes and monocytes from the PBMCs of 
patients suffering from diseases such as leukemia has been demonstrated.  We demonstrated that 
with additional optimization and proper validation, the signaling fingerprint obtainable within 
just a few days post vaccination can serve as a biomarker of a vaccine efficacy.   We 
acknowledge that there are still hurdles in the development of this technique before it is 
applicable for preclinical and clinical usage as a biomarker of therapeutic efficacy.  Biologically, 
more precise signatures to identify entire pathways being activated as well as the activation of 
apoptosis mediators will need to ensue.   The expansion of the signaling panel as well as 
validation of responses at several timepoints will help to achieve a more decipherable, 
reproducible signature of the requirements to induce protective immune responses. In addition, 
although there has already been some standardization and development of a small array to 
minimize variability and increase ease of use, further development and standardization is 
necessary as well as ensuring that it is not cost prohibitive.   We believe that the uses of a 
signaling fingerprint as a biomarker of immune function has great potential and if realized could 
lead to advances in the evaluation of immunogenicity. Deciphering signaling fingerprints would 
yield an immediate appraisal of the effectiveness of a therapy, could be a very early predictor of 
outcome of disease, and may prove to be a useful tool to predict the treatment strategy that would 
be most useful for an individual based on the signaling mediators in the environment to which 
the cells are nonresponsive.  Additionally, examination of signaling signatures can be extended 
to various cell types to gain a comprehensive awareness of the microenvironment, and perhaps 
where immune mediators are failing due to immune suppression. 
The recently developed technique of cytometric mass spectrometry, also know as 
CyTof™ (‘cytometry by time of flight’), would address many of the non-biologic technical 
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concerns of the phospho-flow technique.  The limits of fluorescence detection have the majority 
of cytometers able to differentiate up to 13 channels simultaneously, and state of art technology 
allows up to 17 markers of detection(177).  This limits the phospho-flow technique in the detail 
that it can extrapolate from samples due to limits in reagents.  Moreover, the compensation 
between channels becomes increasingly complex as the number of markers increases and can 
complicate the interpretation of the data.  In addition, another major limitation is cellular auto-
fluorescence, which is not an issue with CyTof™. CyTof™ uses time of flight mass 
spectrometry coupled with heavy metal elemental tags to deliver a sensitive, high-resolution 
ability to analyze cellular markers(178).  Although early studies have used approximately 30 
parameters simultaneously, up to 100 different markers could be used theoretically(178).  In 
preliminary studies, intracellular and surface CyTof™  analysis has revealed detailed signaling 
patterns of cellular subsets that were not possible to detect via phospho-flow(179).    
An evident trend seen in a diverse array of immunotherapies in clinical trials, is the need 
for new additional parameters and biomarkers to evaluate the efficacy of treatments and better 
correlates of long-term disease outcome. The Response Evaluation Criteria in Solid Tumors or 
World Health Organization standard of initial regression of tumor size used for chemotherapeutic 
agents may not be a true evaluation of the effectiveness of an immunotherapeutic agent due to 
the length of time it may take to mount an immune response as well as the immunosuppressive 
environment that may need to be overcome(1, 180). Increasing clinical data has demonstrated 
that some patients that initially demonstrated tumor growth went on to develop long-term 
survival with tumor control or regression. Several initiatives to revise the standards of 
immunotherapeutic evaluation have resulted in new criteria to develop more meaningful 
endpoints: detection of reproducible biomarkers of early cellular activation with minimal 
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variability in the assay and correlation to clinical outcome, identification of clinically measurable 
patterns of anti-tumor immunity by new immune related criteria, and different statistical 
approaches for survival analysis(181).   
We hypothesized that the identification of early intracellular signaling of T cells induced 
within a day after vaccination may serve as a biomarker of the effect of therapy on the immune 
response and correlate with disease outcome.  T cell signatures could be obtained prior to 
treatment in order to assess the host environment, any detectable deficiencies in the immune 
response, and perhaps some insight into the cellular composition of the population. The response 
patterns may be able to direct clinicians to what therapeutic strategies could best benefit an 
individual patient.  Importantly, fingerprints of T cell activation could be assessed early post-
therapy to identify if patients are responding to treatment.  If the signaling signature of a patient 
does not progress post therapy to that of a protective immunity inducing ‘fingerprint’, therapeutic 
options could be readdressed.  This would bypass the need to wait for months or years to 
determine disease outcome providing a better opportunity to successfully create long lasting 
immunity.  Although the phospho-flow technique used to decipher T cell signatures may be too 
variable between samples and challenging to optimize to decipher signaling signatures of in vivo 
events, we were able to distinguish differences and similarities to responses across different 
vaccine designs and host environments. Evidence of differences in T cell signaling signatures in 
response to different therapeutic regimens as well as differences in response to 
microenvironments is promising as a potential parameter by which to evaluate efficacy of 
immunotherapies, in particular prophylactic vaccines in which efficacy and outcome of potential 
disease are exceedingly long-term investigations.  
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Currently most immunotherapies are targeting a single antigen(182) but creation of 
vaccines against multiple tumor antigens may provide a more robust immune response against a 
tumor and prevent evasion of the immune response(183-185).  Intricate model systems would 
need to be developed to determine differences in the efficacy of multiple tumor antigens 
including varying concentrations of antigens, variety of antigens, and combinations of antigens.  
The combination of multiple immune therapies targeting different stages or aspects of tumor 
progression has shown promise in the clinical setting.  Treatment of melanoma patients with IL-2 
and gp100 induced control of tumor growth(186).  Countless therapeutic amalgamations could 
exist, such as combined CTL-4 and PD1 antibody therapies to prevent negative regulation of T 
cell activation and effector mechanisms (1). The detection of a ‘fingerprint’ of a signaling 
signature of protective immune responses versus that of tolerant immune responses could 
simplify and hasten preclinical modeling of different immunotherapeutic regimens by 
streamlining the process. As the current trend in cancer immunotherapy is the combination of 
multiple immune therapies, simplification, standardization, and high throughput parameters of 
evaluation are going to become significantly more important.  New parameters such as 
‘synergistic toxicity’ will need to be assessed(1). Identification of the best combination of 
candidates, consideration of the stage of the immune response to target, and the dose and 
schedules of the immunotherapeutic regimens in order to evaluate efficacy and choose those that 
are most effective will become increasingly complex.  
Adding to the complexity, an important and interesting finding is that many of these 
tumor-associated antigens are not only found in malignancies but after disease or other severe 
inflammatory events.  T cells specific for the abnormal form of MUC1 have been found and 
expanded in vitro from not only cancer patients but healthy individuals as well (87, 92).  
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Antibodies to abnormal MUC1 have been detected in women during lactation or with 
mastitis(187).  Infection of cells by the herpesviridae family members, VZV(188) and 
CMV(189), leads to the overexpression of cyclin B1 and its detection in the cytoplasm.  In these 
instances the immune system is building a memory response to multiple initiating events that 
may cause a cell to react in a certain way.  Therefore, earlier events in life may cause memory 
that is protective for an individual from cancer or encounters with a newly encountered infection 
later in life.  Recent studies have shown that women having experienced two or more severe 
inflammatory events that most likely lead to abnormal MUC1 expression (viral infection such as 
mumps, pelvic surgery, mastitis, etc.) showed a significant reduction in their risk of ovarian 
cancer(190). These data suggest that universal vaccines may be developed that would encompass 
boosting the immune response against cancer and infectious agents simultaneously.  If a 
universal vaccine is to come to fruition, the ability to quickly analyze the immune response to 
different antigens and combinations there of will be very important.  Again, the use of phospho-
flow or a similar technique to distinguish the signaling ‘fingerprint’ of targeted immune cells 
after therapeutic intervention could serve as a biomarker of vaccine efficacy and an early 
indicator of whether or not the therapeutic regimen is inducing the desired productive/protective 
response.  Defining a protective signaling signature of immune cells could serve as a biomarker 
of vaccine efficacy in addition to standard immunogenicity parameters that would be 
representative of a universal robustness and protective response against many disease initiating 
events. 
A T cell signaling ‘fingerprint’ would also serve as a useful tool in other fields such as 
transplantation.  T cell signatures of tolerance induction could aid in the determination of 
immune suppression in patients before a transplanted organ was lost or damaged.  These 
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signaling signatures could, of course, aid in the development of new therapeutics as well as 
provide individual patient feedback on the suppressive therapies that would work best for the 
individual, similar to that discussed above.  Immune signaling fingerprints have the capacity to 
be strong universal biomarkers that are prognostic in that deficiencies in the immune response 
that make an individual more susceptible may be identified, and predictive of whether a therapy, 
prophylactic or therapeutic, will induce the desired immune response.  
 
 83 
APPENDIX A 
Appendix A has been adapted from Reichenbach, D.K., Li, Q, Hoffman, R.A, Williams, A.L., 
Shlomchik, W.D., Rothstein, D.M., Demetris, A.J., and Fadi G. Lakkis. Allograft Outcomes in 
Outbred Mice. 2013. American Journal of Transplantation; with permission from John Wiley 
and Sons.  Copyright permission is kept on file with Dawn K. Reichenbach. 
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A.1 ABSTRACT 
Inbreeding depression and lack of genetic diversity in inbred mice could mask unappreciated 
causes of graft failure or remove barriers to tolerance induction.  To test these possibilities, we 
performed heart transplantation between outbred or inbred mice.  Unlike untreated inbred mice 
in which all allografts were rejected acutely (6-16 days post-transplantation), untreated outbred 
mice had heterogeneous outcomes, with grafts failing early (<4 days post-transplantation), 
acutely (6–24 days), or undergoing chronic rejection (>75 days).   Blocking T cell costimulation 
induced long-term graft acceptance in both inbred and outbred mice, but did not prevent the early 
graft failure observed in the latter.  Further investigation of this early phenotype established that 
it is dependent on the donor, and not the recipient, being outbred and that it is characterized by 
hemorrhagic necrosis and neutrophilic vasculitis in the graft without pre-formed, high titer anti-
donor antibodies in the recipient.  Complement or neutrophil depletion prevented early failure of 
outbred grafts, whereas transplanting CD73-deficient inbred hearts, which are highly susceptible 
to ischemia-reperfusion injury, recapitulated the early phenotype.  Therefore, outbred mice could 
provide broader insight into donor and recipient determinants of allograft outcomes but their 
hybrid vigor and genetic diversity do not constitute a uniform barrier to tolerance induction. 
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A.2 INTRODUCTION 
Inbred mouse strains have been instrumental in uncovering fundamental immunological 
mechanisms that underlie transplant rejection.  The utility of the inbred mouse as a pre-clinical 
model for testing transplantation tolerance strategies, however, has been more limited (191, 192).  
Administration of biological agents that readily induce tolerance in inbred mice, for example, 
often fail in large animals and humans.  Failure has been attributed to the evolutionary separation 
(~ 65 million years) between mice and humans, reduced exposure of laboratory mice housed in 
barrier facilities to microbial pathogens, and/or the biological consequences of inbreeding (191, 
192).  The latter include inbreeding depression and restricted genetic diversity within and 
between inbred mouse strains (193-195).  
Known discrepancies between mice and humans that can be attributed to evolutionary 
separation span both innate and adaptive immunity (196).  Humanized mice in which the human 
immune system has replaced that of the mouse are beginning to elucidate the importance of these 
differences (197), but it remains unclear whether they are superior to inbred mice as pre-clinical 
models of organ transplantation.  The impact of specific-pathogen free (SPF) housing on the ease 
by which transplantation tolerance can be induced in laboratory mice, on the other hand, is 
supported by heterologous immunity studies.  Mice previously exposed to microbial pathogens 
generate memory T cells that cross-react with allogeneic MHC molecules and become resistant 
to tolerance-inducing agents (198-200).  In contrast, naïve laboratory mice harbor less memory T 
cells and can be readily made to accept MHC-mismatched allografts.  As cross-reactive memory 
constitutes a substantial component of the human alloreactive T cell repertoire (201, 202), 
heterologous immunity could provide one explanation why transplantation tolerance strategies 
that succeed in mice often fail in humans. 
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In addition to their rich repertoire of alloreactive memory T cells, humans are an outbred 
species characterized by considerable heterozygosity and genetic diversity.  Both traits contribute 
to the vigorous yet diverse immune responses of humans; raising the possibility that outbreeding 
among humans is an important reason why transplantation tolerance or allograft acceptance 
strategies do not translate uniformly from inbred mice to patients.  Except for one study in which 
outbred mice were found to require more stringent immunosuppression than their inbred 
counterparts to achieve islet allograft survival (203), the effect of outbreeding on allograft 
outcomes, particularly clinically-relevant vascularized grafts, has not been tested yet.  Here we 
investigated the effects of outbreeding in the donor, recipient or both on the survival of 
vascularized heart allografts in mice. 
A.3 METHODS 
A.3.1 Mice 
B6 male mice (6-8 weeks old) (Jackson Laboratory), non-sibling, CD-1 and CF-1 outbred male 
and female mice (4 weeks old) (Charles River Laboratory; CRL), and BALB/c, FVB, and SJL 
inbred male mice (6-8 weeks old) (also from CRL) were housed under SPF conditions.  B6 
CD73-/- mice were a generous gift from Linda F. Thompson (Oklahoma Medical Research 
Foundation).  Serum and tail snips were obtained prior to transplantation.   PCR analysis to type 
MHC II loci was performed at CRL (204).  All procedures were IACUC approved. 
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A.3.2 Transplantation and Tissue Processing 
Vascularized, heterotopic cardiac transplantation was performed as described (205).  Vascular 
anatomy was similar between inbred and outbred mice and surgical mortality was equivalent in 
the two groups (3.8% and 4.3%, respectively).  Grafts were monitored daily and harvested upon 
cessation of palpable heartbeat or after 75 days.  Serum was collected at harvest and graft tissue 
was snap frozen and embedded in OCT (Sakura Finetek), or paraffin and stained with 
hematoxylin and eosin (H&E).  Histological analysis was performed by AJD in a blinded 
fashion.  Donor splenocytes and thymocytes were harvested at time of surgery. 
A.3.3 Mouse Treatment 
15 mg/kg MR1 (anti-CD40L mAb) and 15 mg/kg CTLA-4-Ig (BioExpess and BioXCell) were 
given i.p. on days 0, 2, 4, and 6 to induce long-term graft survival.   C3 was depleted by injecting 
10 units cobra venom factor (CVF) (Quidel Corporation) in 3 divided doses i.p. one day before 
transplantation.  Neutrophils were depleted by injecting 250ug anti-Ly6G (1A8) antibody 
(BioXCell) i.v. one day prior to transplantation (206).  Adenosine analog 5′-N-
ethylcarboxamidoadenosine (NECA) (Sigma) was administered to CD-1 donors (0.1 mg/kg) and 
CD-1 recipient mice (0.01 mg/kg) i.p. 4 hours prior to transplantation. 
A.3.4 Agglutination Assay 
A panel of RBCs from 10 outbred mice were incubated with pre-transplant serum (diluted 1:2) 
from 7 outbred mice that had accelerated graft loss for 30 minutes at 37°C, centrifuged at 400g, 
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resuspended, and examined for agglutination.  If agglutination was absent, the plate was washed 
and 10 µg anti-mouse-Ig (Chemicon) added to each well before re-assessing for agglutination. 
A.3.5 Flow Cytometry 
To measure pre-formed antibodies to donor MHC, serum was diluted 1:2 and incubated with 
thymocytes from their respective donors for 20 minutes at 4°C, stained with anti-IgM and anti-
IgG antibodies (BD Biosciences) and analyzed on an LSRII cytometer. 
A.3.6 Immunofluorescence 
Antibody deposits were examined in allografts transplanted between outbred mice.  As a positive 
control, we transplanted BALB/c hearts into C57Bl/6 mice pre-sensitized by transplanting 
BALB/c skin grafts10 days earlier.  Allografts were harvested at 6 or 12 hours post 
transplantation and frozen in OCT.  6 µm sections were fixed, blocked (Vectabond ABC 
Blocking Kit, Vector Laboratories), and stained with FITC-conjugated anti-IgG or anti-IgM 
(Zymed Laboratories) at room temperature for 1 hour.  To identify neutrophils, sections were 
incubated with unconjugated anti-Ly6G and biotin conjugated CD31 (eBioscience) overnight at 
4°C.   After incubating with secondary antibodies, the tissue was counterstained with DAPI 
(Molecular Probes). 
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A.3.7 Enzyme-linked Immunosorbent Assay (ELISA) 
C3 serum levels were measured pre-transplantation and on days 1, 5, 7, and 11 after 
transplantation using mouse C3 ELISA kit (Kamiya Biomedical) per manufacturer’s instructions. 
A.3.8 Statistical Analysis 
Flow cytometry data is shown as mean fluorescent intensity (MFI) and standard error of mean 
(SEM), and analyzed by unpaired Student’s T-test.  Presence or absence of early graft failure 
was analyzed using a two-sided Fischer’s exact test.  Median survival time (MST) comparisons 
were performed by Gehan-Breslow-Wilcoxon test. 
A.4 RESULTS 
A.4.1 Genetic diversity of outbred mouse stocks 
CD-1 and CF-1 outbred mouse stocks, defined as closed populations of genetically variable 
animals that are bred to maintain maximum heterozygosity (207), were used as either donors or 
recipients of heart grafts.  Mice from either stock displayed outbred vigor judged by greater body 
weight and larger litter size than inbred strains (http://www.criver.com).  To determine their 
diversity, we genotyped class II H-2 loci by PCR.  Of 12 alleles that were genotyped, four (p, b, 
q, and u) were represented in the CD-1 (n = 364) and five (p, b, q, u, and k) in the CF-1 stock (n 
= 79), resembling the diversity of an isolated ‘island’ population (208).  The extent of 
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heterozygosity at these loci was 0.60 and 0.74 in the CD-1 and CF-1 stocks, respectively, which 
is similar to the average heterozygosity of feral mice and humans (208).  Therefore, the outbred 
mouse stocks used in this study are somewhat limited in their diversity but maintain a significant 
degree of heterozygosity typical of outbred populations. 
A.4.2 Blocking T cell costimulation induces long-term allograft acceptance in outbred mice 
We hypothesized that a standard tolerogenic regimen that induces allograft acceptance in inbred 
mice would be less effective in outbred mice.  This was tested by comparing the survival of heart 
allografts transplanted between disparate inbred mouse strains (BALB/c to B6, n = 41) to that of 
allografts transplanted between non-sibling outbred mice (CD-1 to CD-1, n = 33, or CF-1 to CD-
1, n = 28).  Recipients were either left untreated or received a combination of CTLA4-Ig and 
anti-CD154 (MR1) to block T cell costimulation at the time of transplantation.  As expected, T 
cell costimulation blockade induced 100% allograft acceptance (graft survival > 75 days) in the 
inbred group while all untreated recipients rejected their allografts acutely (MST = 8 days) (Fig. 
1a).  In contrast, graft outcomes were not uniform in the outbred group (Fig 1b).  In untreated 
mice, grafts failed either very early (1 - 4 days after transplantation, 10/35 or 29%), acutely (6 - 
24 days, 19/35 or 54%), or underwent chronic rejection (> 75 days, 6/35 or 17%) with graft MST 
remaining similar to that of the inbred group (10 vs 8 days, p = 0.52).  In treated, outbred mice, 
the response was dichotomous with 7/26 (27%) losing their grafts very early and 19/26 (73%) 
achieving long-term graft survival.  The rate of graft acceptance in the treated, outbred group 
was significantly greater than that in the untreated outbred group (73% vs 17%, p < 0.0001).  
Treated, outbred recipients that did not manifest the unusual early graft failure went on to have 
100% (19/19) long-term allograft acceptance similar to the treated inbred group.  Allograft 
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acceptance after costimulation blockade occurred independent of outbred stock combination used 
(69% in CD-1 to CD-1 and 80% in CF-1 to CD-1, n = 16 and 10, respectively, p = 0.67).  
Histopathological analysis revealed mild cellular infiltration, minimal fibrosis, and focal chronic 
vasculopathy (intimal thickening) in long-term accepted allografts in the treated inbred and 
outbred groups, while long-term surviving allografts in the untreated outbred group exhibited 
chronic rejection, ranging from severe to focal (Fig. 1c).  These data indicate that genetic 
diversity and heterozygosity (hybrid vigor) lead to more heterogeneous graft outcomes in 
untreated mice but do not constitute a uniform barrier to graft acceptance after induction therapy. 
 
Figure 4-1.  Effect of costimulation blockade on allograft survival in inbred and outbred mouse groups. 
Survival of (a) inbred Balb/c allografts transplanted to inbred B6 recipients (I to I) and (b) outbred (CD-1 or CF-
1) allografts transplanted to outbred CD-1 recipients (O to O) was assessed in the presence or absence of 
recipient treatment with costimulation blockade (MR-1 + CTLA4-Ig).  (c) Histopathology (H&E) of allografts 
that survived > 75 days in treated I to I group (left panel) and either treated or untreated O to O groups (right 
panels).  Magnification = 2x.  Insets show evidence of chronic allograft vasculopathy in all groups 
(magnification = 30x). 
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A.4.3 Increased early graft failure in outbred mice 
An unexpected finding that emerged from the above experiments is that all treated, outbred mice 
that lost their allografts (27%) did so between 1 and 4 days after transplantation (Fig. 1b).  This 
accelerated graft loss was also observed in a similar proportion (29%) of untreated mice in the 
outbred group (Fig. 1b), but in none (0/41) of the untreated or treated mice in the inbred group  
(p < 0.0001; Fig. 1a).  Early graft failure was not influenced by the particular outbred stock 
combination used (33% in CD-1 to CD-1 and 21% in CF-1 to CD-1, p = 0.40).  The gross 
morphology and histopathology of early graft failure were distinct from classical acute cellular 
rejection (Fig. 2).  Allografts that failed very early were significantly enlarged and were dark in 
color.  Histopathology revealed extensive hemorrhagic necrosis with neutrophilic margination 
and focal neutrophilic arteritis without mononuclear cell infiltration (Fig. 2, left panels).  In 
contrast, acutely rejected hearts in the untreated outbred group exhibited typical severe acute 
lymphocytic infiltration with arteritis (Fig 2, right panels).  These findings suggest that the 
unusually high early graft failure observed exclusively in the outbred group is caused by an 
inflammatory or innate immune process.  
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Figure 4-2.  Histopathology of early graft failure 
 
Representative pathology of cardiac allografts transplanted between untreated outbred mice that failed < 4 days 
(left panels) or between 6 and 24 days (right panels) after transplantation is shown.   Gross appearance of 
allografts is shown in the top panels, H&E stained tissue sections in the middle panels (magnification = 4x), and 
immunofluorescent stained tissue section in the bottom panel.  Insets in left middle panel highlight areas of 
neutrophil clot and neutrophilic vasculitis, while inset in right middle panel demonstrates lymphocytic arteritis 
typical of untreated acute cellular rejection.  Note large area of hemorrhagic necrosis in the early graft failure but 
not acute cellular rejection phenotype.  Ly6G, CD31 and DAPI identify neutrophils, endothelial cells, and nuclei, 
respectively (bottom panel; magnification = 20x). 
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A.4.4 Early graft failure is dependent on donor’s outbred status 
Data from mouse and human studies suggest that allograft outcomes are not only determined by 
the recipient’s genetic background but also by that of the donor.  To investigate whether recipient 
or donor outbred status is responsible for early graft failure, we transplanted inbred (BALB/c) 
hearts into outbred CD-1 mice and vice versa.  Donors and recipients were weight-matched to 
avoid unanticipated surgical complications that could arise from transplanting grafts into size-
mismatched recipients.  In untreated recipients, early graft failure was observed in 7/26 (27%) of 
inbred recipients of outbred hearts (outbred to inbred, O to I, group) but in none of the outbred 
recipients of inbred grafts (inbred to outbred, I to O, group) (Fig. 3a).  The donor outbred status 
effect was also observed in immunosuppressed recipients.  Costimulation blockade induced 
100% allograft acceptance in the inbred to outbred group, while 5/10 (50%) of grafts failed in the 
first 4 days in a similarly treated outbred to inbred cohort (Fig. 3b).  Analysis of all outbred to 
outbred or outbred to inbred transplantation experiments showed that graft outcome (early 
failure, acute rejection, and chronic rejection) did not correlate with the degree of MHC class II 
mismatch between donor and recipient (Fig. 3c). 
Since CD-1 animals were originally derived from the Swiss mouse stock (207), we then 
asked whether early graft failure is determined by genetic determinants specific to the Swiss 
background.  To answer this question, we performed heart transplants using inbred Swiss strains 
as either donors (SJL to C57Bl/6, n = 23) or as both donors and recipients (SJL to FVB, n = 9).  
Of these, only 1/23 (3%) (p = 1.0 compared to I to I group) in the former and none in the latter 
group exhibited the early graft failure phenotype, indicating that the Swiss background of CD-1 
mice does not account for the high incidence of early graft failure observed in the outbred to 
inbred (Fig. 2a & 2b) or in the outbred to outbred (Fig. 1b) transplantation experiments. 
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Figure 4-3.  Early graft failure is dependent on donor outbred status 
Survival of cardiac allografts transplanted from inbred to outbred (BALB/c to CD-1; I to O) or outbred to inbred 
(CD-1 to BALB/c; O to I) mice in the absence (a) or presence of costimulatory blockade (b).   Note complete 
absence of early graft failure phenotype in recipients of allografts from inbred donors.  (c) Degree of MHC II 
mismatch between all donor-recipient pairs used in this study as well as contemporaneous experiments involving 
outbred mice.  Note that the degree of MHC II haplotype disparity between donor and recipient does not 
correlate with graft loss or rejection phenotype. 
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A.4.5 Role of antibodies in pathogenesis of early graft failure 
The histopathology of early graft failure described above bears striking resemblance to that of 
hyperacute rejection observed in sensitized transplant recipients who harbor pre-formed anti-
bodies against donor ABO or HLA antigens (209, 210).  We therefore tested for such antibodies 
in the pre-transplantation serum of mice that went on to develop early graft failure.  Neither pre-
transplantation serum from 7 such recipients (all outbred) nor serum from additional 10 
untransplanted outbred mice caused agglutination of blood from a panel of 10 unrelated outbred 
mice (data not shown), indicating absence of significant pre-formed hemagglutinins.  These 
results are consistent with reported lack of demonstrable expression or function of blood group 
antigens in mice (211, 212).  We then tested whether recipients that went on to develop early 
graft failure had pre-formed IgG or IgM antibodies against donor MHC by incubating pre-
transplantation serum with donor thymocytes.  As shown in Fig. 4a, no anti-donor IgG antibodies 
were detected while a small increase in IgM antibodies over that found in pre-transplantation 
serum of one cohort of mice (O to I) that developed acute rejection could be identified, with the 
caveat that all groups had very low IgM levels to start with.  These data indicate the absence of 
significant pre-formed IgG or IgM anti-MHC antibodies in recipients that develop early graft 
failure but do not rule out the presence of antibodies directed at other tissue antigens.  To explore 
the latter possibility, we assessed antibody binding to graft tissue 6 and 12 hrs after transplanting 
outbred hearts into inbred recipients.  IgM and IgG could not be detected at 6 & 12 hrs in grafts 
that already displayed early histopathologic evidence of hemorrhagic necrosis (Fig. 4b).  Grafts 
harvested from prior experiments that had already developed conspicuous hemorrhagic necrosis 
at 24 hrs after transplantation stained strongly with fluorescein-conjugated anti-IgM or anti-IgG 
antibodies (micrographs not shown).  The presence of significant tissue damage and hemorrhage 
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at the 24 hr time point, however, makes it likely that fluorescein conjugated antibodies bound to 
complement and Ig in the extravasated blood rather than in the heart tissue.  These data therefore 
rule out the presence of significant, pre-formed, anti-donor antibodies in recipients that develop 
early graft failure but do not exclude a contribution of low titer antibodies to the observed 
pathology. 
 
Figure 4-4. Lack of significant, preformed anti-donor antibodies in recipients that exhibited early graft 
failure  
(a) Pre-formed, anti-donor thymocyte IgG (left panel) and IgM (right panel) antibodies in serum of recipients of 
outbred allografts that went on to develop early graft failure. Serum was obtained prior to transplantation in all 
mice except the sensitized group.  MFI of isotype control antibody was subtracted in each case to determine net 
binding of IgG or IgM antibodies to donor thymocytes. (b) IgG and IgM deposits in cardiac allografts harvested 
at indicated time points after transplantation.  (Top panels (positive control) show IgG and IgM deposits in 
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A.4.6 Early graft failure is dependent on complement activation and neutrophils 
Because of the characteristics of the early graft failure phenotype observed so far, we sought to 
investigate innate mechanisms that could contribute to this process.  We first depleted circulating 
C3 in outbred donor and recipient mice by administering cobra venom factor (CVF) around the 
time of transplantation.  We found that C3 depletion completely abrogated early graft failure (n = 
0/20, p = 0.02 compared to untreated O to O group) (Fig. 5a), but as C3 levels returned to 
baseline, 5 heart grafts failed between days 8 and 18 after transplantation with histopathologic 
manifestations of hemorrhagic necrosis (Fig. 5a).  These results establish a cause-effect 
relationship between the complement cascade and early graft failure.  They also confirm that the 
early hemorrhagic necrosis phenotype is not a reflection of an unanticipated high surgical failure 
rate but is a consequence of a biological process dependent on complement activation. 
Since neutrophil infiltration and neutrophilic vasculitis were prominent features of grafts 
that failed very early (Fig. 2), we then investigated the effect of neutrophil depletion on the 
incidence of early graft failure.  As shown in Fig. 5b, only 2/25 (8%) of neutrophil-depleted 
inbred recipients of outbred allografts developed hemorrhagic necrosis, which is significantly 
less than the incidence observed in control, neutrophil-replete mice (7/26 or 27%, p = 0.03).  Of 
the two grafts that had hemorrhagic necrosis in the neutrophil-depleted group, one failed on day 
BALB/c cardiac allografts 12 hrs after transplantation to sensitized C57Bl/6 mice.  Middle and bottom panels 
show lack of IgG and IgM deposits in outbred allografts (CD-1 to CD-1) harvested at 6 and 12 hrs after 
transplantation.  These grafts had evidence of interstitial congestion, focal neutrophilic margination, and platelet 
fibrin thrombi at 6 hrs, and hemorrhagic necrosis with moderate neutrophilic margination at 12 hrs (H&E 
micrographs), consistent with early graft failure phenotype (magnification = 2x, inset magnification = 30x). 
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2 with significant neutrophil infiltration, suggesting incomplete neutrophil depletion of the 
recipient.  The other failed on day 7, again with conspicuous neutrophil but no mononuclear cell 
infiltration, suggesting that early graft failure phenotype could have been precipitated by return 
of neutrophils to the circulation.  These data indicate that neutrophils are important contributors 
to the pathogenesis of early graft failure. 
 
Figure 4-5.  Early graft failure is dependent on complement and neutrophils.   
Survival of cardiac allografts after complement depletion in both donors and recipients (CD-1 to CD-1; O to O) 
(a) or after neutrophil depletion in the recipients (CD-1 to BALB/c; O to I) (b).  Transplantation was performed 
on day 0.  Average C3 levels in recipient blood are depicted as % of baseline level (right-hand y-axis in (a)).  
*Grafts that exhibited early graft failure phenotype by gross morphology and/or histopathology.  H&E 
micrographs confirmed hemorrhagic necrosis and neutrophilic vasculitis in these grafts (magnification = 2x, 
inset magnification = 30x).  
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A.4.7 Increasing the transplanted tissue’s susceptibility to ischemia-reperfusion injury 
recapitulates early graft failure 
The pathology and mechanisms of early graft failure described so far suggest that donor factors, 
possibly related to susceptibility of donor tissues to ischemia-reperfusion (I/R) injury, contribute 
to the early graft failure phenotype.  To test this hypothesis, we investigated whether 
transplanting heart allografts from inbred CD73-/- donors, known to have exaggerated tissue I/R 
responses (213), recapitulates early graft loss otherwise typical of outbred grafts.  CD73 is an 
ectonucleotidase expressed on endothelial cells that downregulates I/R injury by catalyzing the 
hydrolyis of extracellular AMP to the anti-inflammatory metabolite adenosine (214).  We found 
that CD73-/- B6 hearts transplanted to BALB/c mice exhibit high incidence of early graft failure 
(4/18 or 22%) similar to that of outbred allografts transplanted to inbred recipients (7/26 or 27%, 
p = 1.0).  Histopathology confirmed that early graft failure was due to hemorrhagic necrosis and 
neutrophilic vasculitis.  Conversely, treating donors and recipients with NECA, a broad 
adenosine receptor agonist, abrogated early graft loss in the outbred to outbred model (n = 0/14, 
p = 0.02).  These results suggest that donor factors that underly susceptibility to I/R injury also 
play a role in the pathogenesis of early graft failure after transplantation. 
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A.5 DISCUSSION 
It has been postulated that hybrid vigor and genetic diversity of the outbred human population 
could explain why immune therapies that are successful in inbred mouse models sometimes fail 
in humans (191).  In this study, we found that costimulation blockade induces long-term allograft 
acceptance in outbred mouse stocks implying that hybrid vigor cannot account for the 
discrepancy between humans and inbred mice but does not completely rule out the contribution 
of genetic diversity.  The outbred mouse stocks used in this study have been bred to maintain 
maximum heterozygosity (thus, hybrid vigor) but are still somewhat limited in their genetic 
diversity compared to the human population (208).   It is possible then that costimulation 
blockade may fail to induce allograft acceptance if a more diverse outbred mouse population was 
studied.  Such a population, known as Diversity Outbred (DO) mice, has been recently generated 
but remains limited in its availability to investigators (http://jaxmice.jax.org/strain/009376.html) 
(215).  Investigating allograft outcomes in these mice in the future should resolve whether 
simultaneous presence of maximal heterozygosity (hybrid vigor) and allelic variation (diversity) 
impedes allograft acceptance.  Moreover, it is possible that the contribution of these genetic 
variables is only apparent when outbred mice are housed in non-SPF facilities to increase the 
repertoire of alloreactive memory T cells through heterologous immunity. 
A potentially interesting observation in the outbred to outbred transplantation group (Fig. 
1b) is the occurrence of spontaneous long-term allograft survival (>75 days), albeit with 
significant chronic rejection, in approximately 17% of untreated recipients.  The reason for this 
phenomenon was not addressed in this study but could be related to matching between donors 
and recipients at non-H-2 loci.  By performing a large number of heart transplants between 
inbred mouse strains matched at either H-2 or non-H-2 loci, Peugh et al found spontaneous long-
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term graft survival in 25% of recipients matched at H-2 but mismatched at non-H-2 loci (and 
vice versa) (216), suggesting that non-H-2 loci modulate the rejection response.  Identifying such 
loci may be a difficult undertaking at present as it is likely that many loci with additive or 
opposite effects (quantitative trait loci) exist.  Moreover, the spontaneous long-term allograft 
survival phenotype observed in our study all but disappeared when only donors or recipients 
were outbred (Fig. 3a), implying a complex interplay between donor and recipient determinants.  
This warrants careful analysis in the future. 
A principal finding in our study is the identification of a dramatic, early graft failure 
phenotype characterized by neutrophilic vasculitis and hemorrhagic necrosis in 29 of a total of 
97 outbred grafts (30%), but in only 1 of a total of 94 inbred grafts (1%), transplanted to either 
inbred or outbred mice.  All transplants reported in this study were contemporaneous and were 
performed by the same microsurgeon (Q.L.).  Moreover, surgical mortality, which occurred in 
the first day after transplantation due to failure of the vascular anastomosis, was equivalent in the 
outbred and inbred graft groups (3.8% and 4.3%, respectively).  These facts make it less likely 
that the early graft failure phenotype was a consequence of high technical failure rate in mice 
that received outbred grafts.  The most compelling evidence that early graft failure is a bona fide 
biological phenotype is its abrogation when specific biological mediators were eliminated (for 
example, after complement or neutrophil depletion) and its reappearance at later time points 
when the mediators had rebounded. 
The timing and histopathologic hallmarks of the early graft failure phenotype and its 
dependence on complement but not T cell costimulation strongly indicate that it is caused by 
innate or inflammatory mechanisms.  Although we did not identify the initial trigger of the 
inflammatory cascade that led to acute hemorrhagic necrosis, one possibility is the binding of 
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complement-fixing, low titer antibodies that evaded detection by either serology or 
immunofluorescence.  Carroll and colleagues have shown that natural IgM antibodies present in 
low titers initiate ischemia-reperfusion injury in the heart, intestine, and skeletal muscles (217).  
These antibodies bind to self-antigens exposed after tissue ischemia and are potent activators of 
the complement cascade (218).  Alternatively, IgM antibodies with anti-donor allospecificities 
may have been present in recipients that exhibited the early graft failure phenotype.  Another 
possibility is that hemorrhagic necrosis was triggered by the alternative pathway of complement 
activation, which is independent of antibody binding to the affected tissue.  The role of the 
alternative pathway in the pathogenesis of ischemia reperfusion injury has been established in a 
variety of experimental models (219). 
The predominance of the neutrophil among inflammatory cells infiltrating grafts 
undergoing hemorrhagic necrosis is not surprising.  Neutrophils are attracted to sites of ischemia-
reperfusion injury via many mediators, including products of complement activation.  The early 
graft failure phenotype observed in our experiments bears striking resemblance to accelerated 
rejection of cardiac allografts by IFNγ-deficient mice (220), and to accelerated rejection of IFNγ 
receptor-deficient renal allografts by wildtype recipients (221).  In both cases, microscopic 
examination of the grafts revealed intense neutrophilic infiltration and parenchymal necrosis.  As 
in our model, neutrophil depletion prevented accelerated rejection, further underscoring the 
importance of the neutrophil as a mediator of early inflammatory events after organ 
transplantation. 
Another principal finding in our study is that the early graft failure phenotype was 
dependent on the breeding status of the donor and not the recipient.  That donor factors, 
independent of MHC matching, influence graft outcomes has been documented in both mice and 
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humans (222).  Several studies have pointed to the role of the donor complement system in 
influencing graft outcomes.  For example, donor C3 deficiency leads to prolonged survival of 
kidney allografts while donor deficiency of decay-accelerating factor (DAF) accelerates cardiac 
allograft rejection in mice (223, 224).  What donor factors influenced graft outcomes in our study 
is unclear.  We tested whether differences in expression of the complement regulatory molecules 
DAF and Crry among donors correlate with presence or absence of early graft failure but did not 
find a significant correlation (Reichenbach, Lakkis & Heeger, unpublished).  Our observation 
that inbred CD73-/- donors recapitulate early graft failure suggests that determinants of tissue 
susceptibility to I/R in the donor influence graft outcomes after transplantation.  This warrants 
future studies to test whether CD39, CD73, and adenosine receptor expression in outbred mice 
correlates with graft outcomes. 
The model of hemorrhagic necrosis described in this manuscript underscores the 
importance of the donor in shaping graft outcomes and provides an opportunity to gain better 
understanding of the inflammatory events that lead to graft injury.   Interrupting these events 
could prevent the adverse consequences of ischemia-reperfusion injury on early graft function 
and possibly temper innate responses that adversely affect long-term allograft outcomes (225). 
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